WO2007149490A1 - Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins - Google Patents
Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins Download PDFInfo
- Publication number
- WO2007149490A1 WO2007149490A1 PCT/US2007/014388 US2007014388W WO2007149490A1 WO 2007149490 A1 WO2007149490 A1 WO 2007149490A1 US 2007014388 W US2007014388 W US 2007014388W WO 2007149490 A1 WO2007149490 A1 WO 2007149490A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trimers
- hiv
- env protein
- preparation
- trimer
- Prior art date
Links
- 239000013638 trimer Substances 0.000 title claims abstract description 328
- 238000000034 method Methods 0.000 title claims abstract description 110
- 230000008569 process Effects 0.000 title claims abstract description 91
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 79
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 79
- 230000001177 retroviral effect Effects 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title description 3
- 238000009472 formulation Methods 0.000 title description 2
- 239000003599 detergent Substances 0.000 claims abstract description 113
- 108010078428 env Gene Products Proteins 0.000 claims abstract description 112
- 102100034353 Integrase Human genes 0.000 claims abstract description 111
- 238000002360 preparation method Methods 0.000 claims abstract description 110
- 235000001014 amino acid Nutrition 0.000 claims description 105
- 229920001184 polypeptide Polymers 0.000 claims description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 91
- 235000018102 proteins Nutrition 0.000 claims description 77
- 150000001413 amino acids Chemical class 0.000 claims description 58
- 239000000178 monomer Substances 0.000 claims description 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 51
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 50
- 235000018417 cysteine Nutrition 0.000 claims description 48
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 46
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 43
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 43
- 108090001090 Lectins Proteins 0.000 claims description 37
- 102000004856 Lectins Human genes 0.000 claims description 37
- 239000002523 lectin Substances 0.000 claims description 37
- 238000004587 chromatography analysis Methods 0.000 claims description 36
- 239000000539 dimer Substances 0.000 claims description 31
- -1 polyethylene Polymers 0.000 claims description 28
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 22
- 239000007983 Tris buffer Substances 0.000 claims description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 16
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 13
- 239000004698 Polyethylene Substances 0.000 claims description 12
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 239000001590 sorbitan monolaureate Substances 0.000 claims description 12
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 12
- 108090001126 Furin Proteins 0.000 claims description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 11
- 102000004961 Furin Human genes 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 10
- 239000012930 cell culture fluid Substances 0.000 claims description 10
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 238000001042 affinity chromatography Methods 0.000 claims description 8
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001593 sorbitan monooleate Substances 0.000 claims description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 4
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 3
- 239000012615 aggregate Substances 0.000 description 137
- 229920000136 polysorbate Polymers 0.000 description 137
- 229940024606 amino acid Drugs 0.000 description 52
- 238000000055 blue native polyacrylamide gel electrophoresis Methods 0.000 description 45
- 238000001542 size-exclusion chromatography Methods 0.000 description 44
- 238000004458 analytical method Methods 0.000 description 41
- 230000000694 effects Effects 0.000 description 39
- 238000000746 purification Methods 0.000 description 34
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000012505 Superdex™ Substances 0.000 description 17
- 241000894007 species Species 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- 238000005571 anion exchange chromatography Methods 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 239000000356 contaminant Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000234283 Galanthus nivalis Species 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 9
- 108010036239 CD4-IgG(2) Proteins 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000008857 Ferritin Human genes 0.000 description 7
- 108050000784 Ferritin Proteins 0.000 description 7
- 238000008416 Ferritin Methods 0.000 description 7
- 108010034949 Thyroglobulin Proteins 0.000 description 7
- 102000009843 Thyroglobulin Human genes 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 229960002175 thyroglobulin Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 5
- 101710091045 Envelope protein Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 5
- 101710188315 Protein X Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000002439 negative-stain electron microscopy Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 101800000263 Acidic protein Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000001687 destabilization Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000001617 migratory effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000001236 detergent effect Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108010076805 snowdrop lectin Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SFIHWLKHBCDNCE-UHFFFAOYSA-N uranyl formate Chemical compound OC=O.OC=O.O=[U]=O SFIHWLKHBCDNCE-UHFFFAOYSA-N 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100033041 Carbonic anhydrase 13 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 101000867860 Homo sapiens Carbonic anhydrase 13 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101150082981 KNH1 gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000004322 Lens culinaris Species 0.000 description 1
- 235000010666 Lens esculenta Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229910004835 Na2B4O7 Inorganic materials 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004271 weak anion exchange chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- HIV human immunodeficiency virus
- An effective HIV vaccine should demonstrate an ability to elicit neutralizing antibodies (nAb) that are capable of blocking the fusogenic interaction and entry of HIV with the CD4 receptor on CD4 + helper T cells, mediated by the cell surface viral Env glycoproteins, g ⁇ l20 and gp41. Since the genetic polymorphism of the HTV-I gag and env genes are diverse and constantly evolving due to rapid mutation within individuals (2), the nAbs targeting the gpl20 and gp41 envelope proteins on the viral surface should be capable of blocking the viral interaction with the CD4 receptor and should neutralize viruses from a broad range of subtypes without discrimination.
- Env vaccine candidates One logical design of recombinant Env vaccine candidates is to base the vaccine sequence on currently existing HIV-I isolates prevalent in the infected population.
- several oligomeric env proteins from several different subtypes or "clades” have been described, with subtype B sequences serving as a basis for the majority of those that have been reported (3-11, 29, 31).
- the oligomeric Env protein complex on the surface of the virus is comprised of a gpl20-gp41 heterodimer present in a homotrimer configuration (held together via non-covalent interactions), resembling a "spike" structure.
- glycoproteins are derived from a gpl 60 precursor protein, which undergoes processing and cleavage in the cell to generate gpl 20 and gp41 heterodimers that are then targeted to the surface of the HIV viral envelope (12, 13). Fusion of the virus with the CD4 + cell membrane and oligomerization of the trimer spike is mediated by the gp41 glycoprotein, which is tethered to the virion surface via its transmembrane domain (12, 13).
- subtype B HIV JR subtype B HIV JR .
- FL Env was used as a template into which a disulfide bond was introduced between gpl20-gp4lEc ⁇ o subunits (SOS gpl40), followed by a further modification to gp4l E c ⁇ o (I559P mutation), which successfully allowed for the expression of - stable, cleaved and fully processed oligomeric gpl 40 proteins in a trimeric conformation (SOSIP gpl40) (8-1 1 7 15-17). While immunization of rabbits performed with the engineered HIV-1 JR . FL
- the present invention provides novel modified HIV-I Env protein isolates which are purified as complex trimeric forms that closely resemble the structural Env spikes of the native HIV envelope.
- a novel recovery process for obtaining trimeric Env gpl40 protein is also provided.
- Described herein is the purification and biochemical characterization of HIV-I Env isolates, e.g. a modified subtype A KNHl 144 SOSIP R6 gpl40, derived from a contemporary East African subtype A HIV-I primary isolate, and a modified subtype B 5768.4 SOSIP R6 gpl40, using novel methodologies that are different from currently implemented purification procedures.
- the purified KNHl 144 SOSIP R6 gpl40 and 5768.4 SOSIP R6 gpl40 are trimers, as assessed by BN-PAGE and size exclusion chromatography (SEC).
- This invention provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof s which comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation so treated.
- Env retroviral envelope
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises: (a) subjecting the preparation to lectin chromatography to obtain a trimer-enriched eluate in which aggregate content is reduced; (b) applying the eluate of step (a) to a first diethylaminoethyl (DEAE) sepharose chromatography column in the absence of non-ionic detergent to obtain elutio ⁇ fractions further enriched in trimers; (c) applying trimer- enriched elution fractions from the first DEAE sepharose chromatography column of step (b) to a second DEAE sepharose chromatography column in the presence of non-ionic detergent; and (d) collecting the flow through and wash fractions from the second DEAE sepharose chromatography column in the presence of non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof, which comprises: (a) subjecting the preparation to lectin affinity chromatography to obtain an eluate enriched in trimers and essentially separated from monomer and dimer aggregates and macroglobulin; and (b) subjecting the eluate of step (a) to a first diethylaminoethyl sepharose chromatography column in the absence of ⁇ o ⁇ -i ⁇ nic detergent so as to further remove aggregates in the flow through; and (c) subjecting the eluate of step (b) to a second diethylaminoethyl sepharose chromatography column in the presence of non-ionic detergent so as to recover the trimers of the retroviral Env protein.
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which process comprises subjecting the preparation to size exclusion chromatography in the presence of a non-ionic detergent so as to convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation subjected to the chromatography.
- Env retroviral envelope
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to size exclusion chromatography to obtain eluted fractions; (b) subjecting the eluted fractions of step (a) to anion exchange chromatography; and (c) treating the fractions of step (b) with a non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
- a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to size exclusion chromatography to obtain eluted fractions; (b) subjecting the eluted fractions of step (a) to anion exchange chromatography; and (c) treating the fractions of step (b) with a non-ionic detergent, so as to
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain eluted fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent, so as to thereby recover the trimers of the Env protein.
- a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain eluted fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent, so as to thereby recover the trimers of the Env protein.
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions comprising monomers, dimers, and trimers of the Env protein; (b) subjecting the fractions of step (a) to size exclusion chromatography to obtain fractions comprising dimers and trimers of the Env protein; (c) subjecting the fractions of step (b) to anion exchange chromatography to obtain a fractions in which trimers of the Env protein are separated from dimers; and (d) treating the fractions of step (c) with non-ionic detergent, so as to thereby recover the trimers of the Env protein.
- a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions comprising
- the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HTV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO.2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 511 and said modified gp41 ectodomain polypeptide portion
- the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I 5768.4 isolate or such quasi- species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising
- FIGURE 1 Analysis of purified KNHl 144 SOSIP R6 gpl40 trimer and gpl20 monomer.
- Purified KNH 1144 gpl20 monomer (left panel, gp!20) and SOSIP R.6 gpl40 trimer were analyzed by reducing (left panel, SOSIP R6, Red) and non-reducing SDS-PAGE (left panel, SOSIP R6, NK). Proteins were visualized by Coomassie G-250 stain.
- Purified trimer was also analyzed via ARP31 19 western blot on non-reducing SDS-PAGE to examine presence of SDS- insoluble aggregates (middle panel, Anti-Env blot).
- the numbers on the left represent the migratory positions of the molecular weight standard proteins.
- the right panel shows BN-PAGE analysis of purified trimer, either untreated or treated with Tween® 20 (SOSIPR6, -/+ lanes) and purified gpl20 monomer in absence or presence of Tween® 20 treatment (gpl20, -/+ lanes).
- Arrows indicate high molecular weight (HMW) aggregate, trimer and gpl20 monomer species.
- A/ stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards.
- FIGURES 2A-2D Tween® 20 conversion experiments.
- A Dose response: Purified KNHl 144 SOSIP R6 gpl40 trimer was incubated with 0 (no detergent control), or 0.1, 0.05, 0.01, 0.001, or 0.0001% Tween® 20 and analyzed by BN-PAGE and Coomassie G-250 stain. Arrows point to HMW aggregate and trimer species. M stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards.
- B Time course: Purified KNHl 144 SOSIP R6 gpl40 trimer was incubated with Tween® 20 for 5 min (left panel) or 10 min (right panel).
- Trimer was either untreated (- lane) or Tween® 20 treated (+ lane). Arrows indicate trimer and HMW aggregate bands.
- C Temperature effect: Purified KNHl 144 SOSIP R6 gpl40 trimer was either untreated (- lane) or treated with Tween® 20 at on ice (O) 3 room temperature (RT) or 37°C. Reactions were analyzed by BN-PAGE and Coomassie G-250 stain. Arrows indicate HMW aggregate and trimer proteins.
- Tween® 20 effect on HMW aggregate and dimer fractions A preparation composed predominantly of HMW aggregate ( > 80%) was untreated (left panel, - lane), or incubated with Tween® 20 (left panel, + lane), and analyzed by BN-PAGE and Coomassie G-250 stain. Solid arrows indicate HMW aggregate and trimer proteins. Preparations composed of HMW aggregate, dimers and monomers were untreated (right panel, - lane) or incubated with Tween® 20 (right panel, + lane) and analyzed by BN-PAGE and Coomassie G-250 stain. Arrows on the right hand side point to aggregate, trimer, dimer and monomer species.
- FIGURE 3 Size Exchange Chromatography (SEC) analysis of KNHl 144 SOSIP R6 gpl40 trimer.
- KNHl 144 SOSIP R6 gp!40 trimer was resolved on a Superdex 200 10/300 GL column in TN-500 buffer containing 0.05% Tween® 20 (TNT-500).
- TNT-500 0.05% Tween® 20
- the A 28O protein profile of the run is shown in the middle panel.
- Fractions B7-C3 from the run were analyzed by BN-PAGE, followed by silver stain (bottom panel). Arrows to the side of the BN-PAGE image point to the trimer.
- the vertical arrow in the BN-PAGE indicates the peak signal of the trimer in fraction B 12.
- the arrow in the middle chromatograph corresponds to fraction B 12.
- FIGURE 4 Effect of Tween® 20 treatment on KNHl 144 SOSIP R6 HMW aggregate antigenicity.
- Lectin ELISA of untreated and Tween® 20 treated KNHl 144 SOSIP R6 HMW aggregate Untreated or Tween® 20-treated HMW aggregate were bound to GNA lectin coated ELISA plates and probed with 2Gl 2, b6, bl2, CD4-IgG2, and HIVIg. The panels represent their respective binding curves.
- Antibody affinity to the untreated HMW aggregate is represented by the curve having diamond lines.
- Affinity to the Tween® 20 treated HMW aggregate is represented by curve having square lines.
- the Y-axis represents the colorimetric signal at OD492 and the X-axis represents antibody concentration in [ug/ml].
- Lectin ELISA of untreated and Tween® 20-treated KNHl 144 SOSIP R6 gpl40 trimer Untreated or Tween® 20 treated trimer (containing 10-15% HMW aggregate) were bound to GNA lectin coated ELISA plates and probed with 2Gl 2, b6, bl2, and CD4-IgG2. The panels represent their respective binding curves. Antibody affinity to the untreated trimer is represented by the curve having diamond lines. Affinity to the Tween® 20 treated trimer is represented by the curve having square lines.
- FIGURE 5 Effect of Tween® 20 treatment on KNHI l 44 SOSIP R6 gpl40 trimer binding to DEAE anion exchange column.
- sample was applied over an anion exchange column (DEAE HiTrap FF 1 ml column) (Load). Flow through (FT) fractions were collected and the column was washed (Wash).
- the column was eluted (Elution) and fractions were analyzed over BN-PAGE, followed by Coomassie G-250 stain.
- the top panel shows fractions analyzed from the untreated control trimer DEAE application.
- the bottom panel shows fractions analyzed from the Tween® 20 treated trimer DEAE application.
- M stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards. Asterisks highlight the fraction where the trimer is found.
- FIGURE 7 SEC analysis of KNHI l 44 gpl20 monomer: KNHl 144 gpl20 monomer was resolved on a Superdex 200 10/300 GL column in TN-500 buffer. The top chromatograph shows its A 280 protein profile of the run. As a control, JR-FL gpl20 monomer was resolved in a similar manner and its A 280 protein profile is displayed in the bottom chromatograph. The observed retention times for both monomers and their apparent calculated molecular weights are indicated.
- FIGURE 8 Tween® 20 effect on a.M: Purified a 2 M was incubated with Tween® 20 (+ lane) or waa untreated (- lane). Reactions were analyzed by BN-PAGE and Coomassie stain. Arrow indicates a 2 M band.
- FIGURE 9 Amino acid sequence (SEQ ID NO:1) of modified gpl40 the HIV-I KNHl 144 isolate.
- FIGURE 10 Nucleic acid sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:4) of H ⁇ V-1 5768.4 isolate.
- FIGURES HA and HB Gel analysis (A) BN-PAGE and (B) SDS-PAGE of purified trimer product using the purification method described in Experimental Details III
- FIGURE 12 Gel analysis (BN-PAGE/Silver) of purified trimer using the purification method described in Experimental Details II (fifth lane) and using the purification method described in Experimental Details III (third lane). Molecular weight marker (first lane).
- FIGURES 13A and 13B Immunoprecipitation (IP) of KNHl 144 SOSIP.R6 using ARP3110 probing antibody (A) using the purification method described in Experimental Details III and (B) using the purification method described in Experimental Details II.
- IP Immunoprecipitation
- FIGURES 14A and 14B Western Blot analysis of KNHl 144 SOSIP.R6 using ARP31 10 probing antibody (A) using the purification method described in Experimental Details III and (B) using the purification method described in Experimental Details II.
- An "A5I 1C mutation” refers to a point mutation of amino acid 51 1 in the HIV-I KNHl 144 isolate gpl20 from alanine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 51 1 in all other HTV isolates. For example, in HIV-I JR . FL the corresponding amino acid is A492 (Genbank Accession No. U63632), in HIV-1 HXB2 the corresponding amino acid is A501 (Genbank Accession No. AAB50262) and in HIV-l NL4 - 3 it is A499 (Genbank Accession No. AAA44992).
- the amino acid may also be an amino acid other than alanine which has similar polarity or charge characteristics, for example.
- This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art.
- This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
- "157 IP" refers to a point mutation wherein the isoleucine residue at position 571 of a polypeptide chain is replaced by a proline residue.
- T617C mutation refers to a point mutation of amino acid 617 in HTV-I KNHl 144 isolate gp41 ectodomain from threonine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 617 in all other HIV isolates.
- HJV-I JR . FL the corresponding amino acid is T596 (Genbank Accession No. U63632)
- HIV-I H XB2 the corresponding amino acid is T605 (Genbank Accession No. AAB50262)
- HIV-1 NL4 -3 the corresponding amino acid is T603 (Genbank Accesion No. AAA44992).
- the amino acid may also be an amino acid other than threonine which has similar polarity or charge characteristics, for example.
- This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art.
- This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
- A519C mutation refers to a point mutation of amino acid 519 in HIV-I 5768.4 isolate gp!20 from alanine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 519 in all other HIV isolates. For example, in HIV-I JR . FL the corresponding amino acid is A492 (Genbank Accession No. U63632), in HIV-1 HXB2 the corresponding amino acid is A501 (Genbank Accession No. AAB50262) and in HIV-1 NL4 . 3 it is A499 (Genbank Accession No. AAA44992).
- the amino acid may also be an amino acid other than alanine which has similar polarity or charge characteristics, for example.
- This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art.
- This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
- I579P refers to a point mutation wherein the isoleucine residue at position 579 of a polypeptide chain is replaced by a proline residue.
- a "T625C mutation” refers to a point mutation of amino acid 625 in HIV-I 5768.4 isolate gp41 ectodomain from threonine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 625 in all other HIV isolates. For example, in HIV-I JR - FL the corresponding amino acid is T596 (Genbank Accession No. U63632), in HIV-] HXB2 the corresponding amino acid is T605 (Genbank Accession No. AAB50262) and in HIV-IN L -U the corresponding amino acid is T603 (Genbank Accesion No. AAA44992).
- the amino acid may also be an amino acid other than threonine which has similar polarity or charge characteristics, for example. This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
- HIV refers to the human immunodeficiency virus. HIV shall include, without limitation, HIV- 1.
- the human immunodeficiency virus (HIV) may be either of the two known types of HIV (HIV-I or HrV-2).
- the HTV-I virus may represent any of the known major subtypes (Classes A, B, C, D E, F, G and H) or outlying subtype (Group O).
- gpl40 envelope refers to a protein having two disulfide-linked polypeptide chains, the first chain comprising the amino acid sequence of the HIV gpl20 glycoprotein and the second chain comprising the amino acid sequence of the water-soluble portion of HIV gp41 glycoprotein ("gp41 portion").
- HIV gpl40 protein includes, without limitation, proteins wherein the gp41 portion comprises a point mutation such as I579P.
- gpl40 envelope comprising such mutation is also referred to as "HIV SOS gpl40", as well as “HIV gpRO monomer” or "SOSEP gpl40".
- gp41 includes, without limitation, (a) whole gp41 including the transmembrane and cytoplasmic domains; (b) gp41 ectodomain (gp4lEc ⁇ o); (c) gp41 modified by deletion or insertion of one or more glycosylation sites; (d) gp41 modified so as to eliminate or mask the well-known immunodominant epitope; (e) a gp41 fusion protein; and (f) gp41 labeled with an affinity ligand or other detectable marker.
- ectodomain means the extracellular region of a transmembrane protein exclusive of the transmembrane spanning and cytoplasmic regions.
- This invention provides a process of recovering trimers of a retroviral envelope (E ⁇ v) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation so treated.
- the retroviral Env protein is an HIV Env protein.
- the retroviral Env protein is an HIV-I or HIV-2 Env protein.
- the above process further comprises formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises: (a) subjecting the preparation to lectin chromatography to obtain a trimer-enriched eJuate in which aggregate content is reduced; (b) applying the eluate of step (a) to a first diethylaminoethyl (DEAE) sepharose chromatography column in the absence of non-ionic detergent to obtain elution fractions further enriched in trimers; (c) applying trimer- enriched elution fractions from the first DEAE sepharose chromatography column of step (b) to a second DEAE sepharose chromatography column in the presence of non-ionic detergent; and (d) collecting the flow through and wash fractions from the second DEAE sepharose chromatography column in the presence of non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
- step (a) the preparation is a concentrated cell culture fluid.
- step (a) the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography.
- step (a) column fractions enriched in trimers are eluted through a linear gradient in PBS to 1.0 M methyl-a-D- mannopyranoside (MMP) in ten column volumes.
- step (b) fractions further enriched in trimers are eluted from the DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes.
- step (c) the fractions further enriched in trimers are eluted from the second DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes.
- the wash fractions of step (d) comprise buffer which comprises 20 mM Tris and 75 mM NaCl, pH 7.5.
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof, which comprises: (a) subjecting the preparation to lectin affinity chromatography to obtain an eluate enriched in trimers and essentially separated from monomer and dimer aggregates and macroglobulin; and (b) subjecting the eluate of step (a) to a first diethylaminoethyl sepharose chromatography column in the absence of non-ionic detergent so as to further remove aggregates in the flow through; and (c) subjecting the eluate of step (b) to a second diethylaminoethyl sepharose chromatography column in the presence of non-ionic detergent so as to recover the trimers of the retroviral Env protein.
- the retroviral Env protein is an HIV Env protein.
- the retroviral Env protein is an HIV-I or HIV-2 Env protein.
- the preparation in step (a), is a concentrated cell culture fluid. In another embodiment, in step (a), the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography. In yet another embodiment, the trimers are recovered in the presence of the non-ionic detergent so as to maintain trimer stability upon subsequent storage.
- the non-ionic detergent is a polyethylene type detergent.
- the polyethylene type detergent is a poly(oxyethylene) sorbitan monolaureate.
- the poly(oxyethylene) sorbitan monolaureate is poly (oxyethylene) (20) sorbitan monolaureate. In one embodiment, the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
- the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate or a mutant derived therefrom.
- the HIV-I subtype A isolate is KNHl 144.
- the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate or a mutant derived therefrom.
- the HIV-I subtype B isolate is 5768.4.
- steps (a) through (d) are carried out at room temperature.
- steps (a) through (c) are carried out at room temperature.
- the non-ionic detergent present is at a concentration of 0.001% to 1% by weight of the preparation.
- the concentration of the non-ionic detergent is from 0.01% to 1% by weight.
- the concentration of the non-ionic detergent is from 0.025% to 1% by weight.
- the concentration of the non-ionic detergent is from 0.01% to 0.5% by weight. In another embodiment, the concentration of the non-ionic detergent is from 0.01% to 0.1% by weight. In one embodiment, the concentration of the non-ionic detergent is from 0.01% to 0.05% by weight. In another embodiment, the concentration of the non-ionic detergent is 0.05% by weight. 14
- the preparation prior to treatment with the non-ionic detergent, comprises greater than 10% high molecular weight aggregates. In another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises 10-40% high molecular weight aggregates. In yet another embodiment, prior to treatment with the non- ionic detergent the preparation comprises greater than 70% high molecular weight aggregates, the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp
- the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HW-I 5768.4 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cyst
- the recovering further comprises purifying the trimers. In one embodiment, at least 50 ⁇ g of trimers are recovered from the preparation. In another embodiment, the above process further comprises formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
- trimer purification methods/processes at least 50 ⁇ g of trimers are recovered from the starting preparation.
- the above processes further comprise formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises subjecting the preparation to size exclusion chromatography in the presence of a non-ionic detergent so as to convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation subjected to the chromatography.
- the retroviral Env protein is an HIV Env protein.
- the retroviral Env protein is an HIV-I or HIV-2 Env protein.
- the process comprises subjecting the preparation to size exclusion chromatography, and then subjecting the resulting preparation to anion exchange chromatography before recovering the trimers.
- the processes of the invention provide trimers which are recovered in the presence of non-ionic detergent so as to maintain trimer stability upon subsequent storage.
- the trimers in non-ionic detergent according to this invention are stable for days, weeks and months, e.g., greater than one week, greater than two weeks, greater than one month, greater than two months, or greater than six months to years, for example, ⁇ 4°C-25°C, at room temperature ( ⁇ 16°C-25°C), or frozen.
- the non-ionic detergent is a polyethylene type detergent.
- the polyethylene type detergent is a poly (oxyethylene) sorbitan monolaureate.
- the poly (oxyethylene) sorbitan monolaureate is poly (oxyethylene) sorbitan monolaureate.
- the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
- the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate, a mutant derived therefrom, or a quasi-species thereof.
- the HIV-I subtype A isolate is KNHl 144.
- the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate, a mutant derived therefrom, or a quasi-species thereof.
- the HIV-I subtype B isolate is 5768.4.
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to size exclusion chromatography to obtain eluted fractions; (b ) subjecting the fractions of step (a) to anion exchange chromatography; and (c) treating the column fractions of step (b) with a non-ionic detergent, so as to thereby recover the trimers of the Env protein.
- the process further comprises re-subjecting the column fractions of step (b) to anion exchange chromatography prior to step (c).
- step (b) approximately 30-40% more trimers are recovered following re-subjecting the fractions of step (b) to anion exchange chromatography.
- the process further comprises re-subjecting the fractions of step (c) to anion exchange chromatography (e.g., DEAE anion exchange chromatography) to remove non-aggregate contaminants.
- anion exchange chromatography e.g., DEAE anion exchange chromatography
- the size exclusion chromatography of step (a) is performed in the presence of a non-ionic detergent.
- the retroviral Env protein is an HIV Env protein.
- the retroviral Env protein is an HlV-I or HIV-2 Env protein.
- This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain elution fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent so as to thereby recover the trimers of the Env protein.
- a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain elution fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent so as to thereby recover the trimers of the Env protein.
- This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions comprising monomers, dimers, and trimers of the Env protein; (b) subjecting the fractions of step (a) to size exclusion chromatography to obtain fractions comprising dimers and trimers of the Env protein; (c) subjecting the fractions of step (b) to anion exchange chromatography to obtain fractions in which trimers of the Env protein are separated from dimers; and (d) treating trimer-containing fractions of step (c) with non-ionic detergent, so as to thereby recover the trimers of the Env proteins.
- a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions compris
- the non- ionic detergent is a polyethylene type detergent.
- the polyethylene type detergent is poly (oxyethylene) sorbitan monolaureate.
- the poly (oxyethylene) sorbitan monolaureate is poly (oxyethylene) (20) sorbitan monolaureate.
- the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
- the process further comprises re-subjecting the fractions of step (c) to anion exchange chromatography following step (c) and prior to step (d). In another embodiment, approximately 30-40% more trimers are recovered following re-subjecting the fractions of step (c) to anion exchange chromatography.
- the process further comprises re-subjecting the fractions of step (d) to anion exchange chromatography to remove non-aggregate contaminants.
- the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
- the preparation prior to treatment with the non-ionic detergent, comprises greater than 10% high molecular weight aggregates. In another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises 10-40% high molecular weight aggregates. In yet another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises greater than 70% high molecular weight aggregates.
- the non-ionic detergent is present at a concentration of between 0.001% to 1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.01% to 1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.025% to 1% by weight of the preparation. In yet another embodiment, the concentration of non-ionic detergent is from 0.01% to 0.5% by weight of the preparation. In a further embodiment, the concentration of non- ionic detergent is from 0.01% to 0.1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.01% to 0.05%. In yet another embodiment, the concentration of non-ionic detergent is 0.05%.
- the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein. In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype A isolate is KNHl 144. In another embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype B isolate is 5768.4.
- This invention also provides processes described above, which further comprise formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
- the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified g ⁇ l20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO:2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 511 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino
- the cysteine at position 51 1 is the result of an A51 1C mutation.
- the cysteine at position 617 is the result of a T617C mutation.
- the proline at position 571 is the result of an I571P mutation.
- the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HTV-I S768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I 5768.4 isolate or such quasi- species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino
- the cysteine at position 519 is the result of ah A519C mutation.
- the cysteine at position 625 is the result of a T625C mutation.
- the proline at position 579 is the result of an I579P mutation.
- the process further comprises purifying the trimers so recovered.
- the present invention as described herein encompasses the purification and biochemical characterization of a KNHl 144 SOSIP R6 gpl40, derived from a contemporary East African subtype A HIV-I primary isolate, using novel methodologies that are different from previously implemented purification procedures.
- the purified KNHl 144 SOSIP R6 gpl40 is a trimer based on BN-PAGE and size exclusion chromatography (SEC) analyses.
- SEC size exclusion chromatography
- the present invention is directed to novel methods involving the use of non-ionic detergents, such as Tween® 20, to recover homogeneous trimeric forms of the KNHl 144 SOSIP R6 Env gpl40 protein from aggregates thereof.
- Trimers are recovered (also termed “collapsed” or “converted”) from aggregrates (of monomers, dimers and trimers) at greater than 90-98% purity, typically 100% purity using non-ionic detergent in accordance with this invention.
- the present invention also provides novel insights into the nature of the aggregate species.
- non-ionic detergent e.g., Tween® 20
- treatment on the antigenic properties of KNHl 144 SOSIP R6 gpl40 aggregates and trimers were examined.
- digital imaging based on negative stain electron microscopy was perform and reveals the structure of purified KNHl 144 SOSIP R6 gpl40 as trimeric oligomers.
- the present invention is further directed to novel methods involving the use of non-ionic detergents, such as Tween® 20, to recover homogeneous trimeric forms of the subtype B 5768.4 SOSIP R6 Env gpl40 protein from aggregates thereof. Trimers are recovered (also termed "collapsed") from aggregates at greater than 90-98% purity, typically 100% purity using non-ionic detergent.
- non-ionic detergents such as Tween® 20
- Trimers are recovered (also termed "collapsed") from aggregates at greater than 90-98% purity, typically 100% purity using non-ionic detergent.
- the KNHl 144 SOSIP R6 envelope and furin DNA plasm ids were as described.
- HEK 293T cells were seeded in triple flasks at a density of 2.5 x 10 7 cells/flask and cultured in DMEM/10% FBS/1% pen-strep with 1% L-glutarnine 24 hours prior to transfection.
- 270 ug of KNHl 144 SOSIP R6 envelope DNA was mixed with 90 ug of Furin protease DNA plasmid (per flask) in Opti-MEM.
- Polyethyleneimine (PEI) was added stepwise (2 mg PEI: 1 mg total DNA) and vortexed immediately in between each addition.
- the PEI/DNA complex solutions were incubated for 20 minutes at room temperature. Complexes were then added to the flasks and incubated for 6 hours at 32°C, 5% CO ⁇ .
- the cells were then washed with warmed PBS and then incubated in exchange media (DMEM/ 0.05% BSA/1% pen-strep) for 48 hours at 32°C, 5% CO 2 . After the 48 hour incubation, the supernatants were collected and a cocktail of protease inhibitors was added to minimize protein degradation. Harvested supernatants were then clarified by filtration through a 0.45um filter and concentrated to 53X.
- KNHl 144 gpl20 monomer has been previously described (1 ) and typically, 1-2 L of cell culture supernatants from transfected cells were harvested. Supernatants were clarified by filtration and stored at -8O 0 C without any concentration prior to purification. Purification of KNHl 144 SOSIP R6 f_pl40 and gpl20:
- KNHl 144 SOSIP R6 gpl40 trimer was purified via a four step process starting with an ammonium sulfate precipitation followed by lectin affinity, size exclusion and ion-exchange chromatography.
- 53X concentrated cell culture supernatant was precipitated with an equal volume of 3.8 M ammonium sulfate to remove contaminant proteins (with the major contaminant being ⁇ -2-macroglobulin).
- the ammonium sulfate was added with constant stirring with a stir bar and then was immediately centrifuged at 4000 rpm, 4°C for 45 minutes.
- the resulting supernatant was diluted 4-fold with PBS, pH 7.25, and was filtered using a 0.45 urn vacuum filter.
- the sample was then loaded at 0.5-0.8 ml/min onto a Galanthus nivalis (GNA) lectin (Vector Laboratories, Burlingame, CA) column equilibrated with PBS- pH 7.25. Once the load was finished, the column was washed with PBS pH 7.25 until OD 2 ⁇ o reached baseline, followed by a second wash with 0.5 M NaCl PBS pH 7.25 at 1 ml/min in order to remove contaminant proteins (mainly BSA). The column was then eluted with 1 M MMP PBS pH 7.25 starting with flowing one half CV through the column at 0.3 ml/min and pausing the purification for a 1 hour incubation in MMP elution buffer.
- GAA Galanthus nivalis
- the fractions were analyzed by BN-PAGE using a 4- 12% Bis-Tris NuPAGE gel (Inv ⁇ trogen, Carlsbad, CA) ( 10). All trimer containing fractions were pooled and diluted to 75 mM NaCl with 2OmM Tris pH 8. The diluted SEC pool was then applied over a 1 ml HiTrap DEAE FF column (GE Healthcare), equilibrated in 20 mM Tris pH 8, 75 mM NaCl (TN-75). The diluted SEC pool was loaded at 0.5 ml/min. The column was washed with TN-75 at 1 ml/min until the OD 2 80 reached baseline. The column was then eluted with 20 mM Tris, 300 mM NaCl pH 8 at 1 ml/min, collecting 0.5 ml fractions.
- the flow-through fraction from the DEAE column was re-applied over the column (equilibrated in TN-75) and typically 20-30% or 30-40% more trimer was recovered in this manner.
- the fractions were analyzed by BN-PAGE and by reducing and non-reducing
- ARP31 19 monoclonal antibody The trimer containing fractions were pooled and trimer concentration was determined through densitometry on a reducing SDS-PAGE gel using IR-FL gp 120 as a standard .
- KNHl 144 gpl20 monomer KNHl 144 gpl20 monomer:
- Unconcentrated cell culture supernatants containing secreted gpl20 monomer were applied directly over a GNA lectin column equilibrated in 20 mM imidazole pH 7.1 at 1-2 ml/min. Following adsorption, the column was washed with a high salt (PBS containing 1 M " NaCl, pH 7.1) wash, followed by a low salt (20 mM imidazole pH 7.1) wash. The column was eluted with 1 M MMP in 20 mM imidazole, 0.2 M NaCl pH 7.1.
- Peak fractions were pooled and diluted with 20 mM imidazole, pH 7.1, thirteen-fold to a final buffer concentration of 20 mM imidazole, pH 7.1, 15 mM NaCl.
- the diluted GNA elution was applied over 1 ml HiTrap Q Sepharose FF (GE Healthcare) equilibrated in 20 mM imidazole, pH 7.1.
- the column was washed with 20 mM imidazole, pH 7.1, and was eluted with 20 mM imidazole, 0.2 M NaCl, pH 7.1.
- Tween® 20 Dose effect: 1 ug of purified KNHl 144 SOSIP R6 trimer was incubated with varying concentrations of Tween® 20 (polyoxyethylene sorbitan monolaurate) ranging from 0 to 0.0001 % (v/v) and incubated for 1 hour at room temperature. Following incubation, samples were analyzed by BN-PAGE as described above.
- Tween® 20 Temperature dependance on Tween® 20 effect: To determine if temperature affected the ability of Tween® 20 to recover trimers from aggregates (i.e., collapse aggregate into trimer), 1 ug of purified KNHl 144 SOSIP R6 trimer was incubated with Tween® 20 to a final concentration of 0.05% (v/v) at 0 0 C (on ice), room temperature (22-23°C) at 37°C, or left untreated for 10 minutes. Following the incubation, samples were analyzed by BN-PAGE and Coomassie staining.
- Tween® 20 effect on KNHl 144 gpl20 To test if Tween® 20 had a similar effect on KNHl 144 gpl20, 1 ug of purified gpl20 monomer was either untreated or incubated with Tween® 20 at a final concentration of 0.05% for 10 minutes at room temperature. Following the treatment, samples were analyzed by BN-PAGE and Coomassie staining.
- Tween® 20 effect on a-2-macroglogulin (a 2 M) 0.5 ug of purified ⁇ -2-macroglobuHn was either untreated or treated with Tween® 20 at a final concentration of 0.05% for 10 minutes at room temperature. Reactions were analyzed via BN-PAGE, followed by Coomassie staining.
- Molecular weight standards SEC A Superdex 200 10/300 GL column was equilibrated in 20 mM Tris pH 8, 0.5 M NaCl (TN-500) and calibrated with the following molecular weight standard proteins: thyroglobulin 669,000 Da; ferritin 440,000 Da; BSA 67,000 Da; and RNAse A 13,700 Da. A standard curve was generated by plotting the observed retention volumes of the standard proteins against the log values of their predicted molecular weights.
- KNHl 144 gp!20 SEC analysis: 14 ug of purified KNH 1144 gp 120 (either untreated or Tween® 20-treated as described above) was applied over the Superdex 200 column equilibrated in TN- 500 and resolved at a flow rate of 0.4 ml/min. As a control, 10-14 ug of JR-FL gpl20 was also analyzed in a similar manner.
- KNHl 144 SOSIP R6 gpUO SEC analysis 8-10 ug of purified KNHl 144 SOSIP R6 gpl40 was treated with Tween® 20 at a final concentration of 0.05% for 10-30 minutes at room temperature. Treated samples were then applied over the Superdex 200 column equilibrated with TN-500 containing 0.05% Tween® 20 (TNT-500) and resolved at 0.4 ml/min, collecting 0.4 ml fractions. Trimer-containing fractions were then analyzed by BN-PAGE, followed by silver staining. Fractions were also separated by BN-PAGE, followed by Western blot analysis with ARP 3119 antibody.
- Human mAbs b6 (32), bl2 (33) and 2Gl 2 (26), HIVIg (40) were obtained from Dr. Dennis Burton (The Scripps Research Institute, La JoIIa 3 CA) or Dr. Herman Katinger (University of Natural Resources and Applied Life Sciences, Austria, Vienna).
- anti-Env antibodies 2G12, b6, bl2 and HIVIg were used.
- the CD4-IgG2 antibody conj ugate PRO 542 (39) was also used .
- ELISA plates were coated overnight at 4°C with lentil lectin powder from Lens culinaris (L9267, Sigma) at 10 ug/ml concentration. Plates were washed with PBS twice and blocked with SuperBlock (Pierce) (warmed to RT). Excess blocking agent was washed off with PBS. SEC fractions containing HMW aggregate were either untreated or treated with 0.05% Tween® 20 (v/v, final concentration) for 30 minutes at room temperature (RT) and were added at 0.3 ug/ml (diluted in PBS) and bound to the plates (via the lectin) for 4 hours at RT.
- Tween® 20 v/v, final concentration
- EM analysis of the SOSIP trimers was performed by negative stain as previously described (34, 35). Because this technique is incompatible with detergent, 20 ⁇ l of the original sample (0.5 mg/ml in TN-300) was dialyzed against BSB (0.1 M H 3 BO 3 , 0.025 M Na 2 B 4 O 7 , 0.075 M NaCl, pH 8.3) and subsequently depleted of detergent using the Mini Detergent-OUTTM detergent removal kit (Calbiochem, La JoIIa, CA) as described by the manufacturer. Two microliters of the resulting protein solution, diluted in 200 ⁇ l BSB, was affixed to carbon support membrane, stained with 1% uranyl formate, and mounted on 600 mesh copper grids for analysis.
- BSB 0.1 M H 3 BO 3 , 0.025 M Na 2 B 4 O 7 , 0.075 M NaCl, pH 8.3
- Mini Detergent-OUTTM detergent removal kit Calbiochem, La JoIIa, CA
- EMs were recorded at XlOO 5 OOO at 100 kV on a JOEL JEM 1200 electron microscope. Measurements were made using the Image-Pro Plus software program. Fifty or more trimers were measured and analyzed statistically. The average diameter of the compact trimers formed by the SOSIP gpl40 (e.g., KNHl 144.R6 SOSIP) proteins was about 12-13 nm.
- SOSIP gpl40 e.g., KNHl 144.R6 SOSIP
- KNHl 144 SOSIP R6 gpl40 trimers typically involved three chromatography steps: GNA lectin affinity, Superdex 200 size exclusion and DEAE weak anion exchange.
- 53X concentrated cell culture supernatant precipitated with ammonium sulfate was clarified by centrifugation, diluted and applied over the GNA lectin affinity column to capture gpl40 proteins via ( ⁇ -1, 3) mannose residues.
- Analysis of the ammonium sulfate precipitation using different starting concentrations of harvested cell culture supernatant (10OX to 40X) revealed that 53X was the optimum condition at which maximum ⁇ -2-macroglobulin precipitated out, with minimal envelope protein loss.
- Typical HMW aggregate content ranged from 10 to 40% of the final preparation prior to non-ionic detergent treatment.
- Treatment of the purified preparation with Tween® 20 at a final concentration of 0.05% converted the HMW aggregate species to trimers, yielding a homogenous trimer preparation ( Figure 1, right panel, SOSIP R6, + lane)(19). It should be noted that treatment with Tween® 20 also caused the treated trimer to migrate slightly more rapidly than the untreated trimer (notice faster mobility of trimer in the + lane).
- Tween® 20 provided a simple and mild means to obtain homogenous trimers, further characterization of the non-ionic detergent effect was performed.
- a purified trimer preparation containing ⁇ 30% aggregates e.g., monomer, dimmer and trimer
- Tween® 20 was treated with Tween® 20 at final concentrations of 0.0001% to 0.1% (v/v) ( Figure 2A).
- the SOSJP R6 aggregates were converted to trimers at concentrations of 0.1% to 0.01% ( Figure 2A, lanes 3-5). No conversion was observed at Tween® 20 concentrations of 0.001 and 0.0001% ( Figure 2A, lanes 6 and 7).
- ⁇ -2- macroglobulin (0. 2 M), which is an acidic 726 kDa tetrameric glycoprotein comprised of four identical 185 kDa subunits, was incubated with Tween® 20. No change was observed in the migratory pattern of Ct 2 M in the presence of Tween® 20, although there was a slight increase in the staining intensity of the protein.
- Tween® 20 To examine whether Tween® 20 could convert preparations containing predominantly aggregate as the major oligomeric species to resulting trimers, a KNHl 144 SOSIP R6 preparation containing > 70% HMW aggregate was incubated with Tween® 20 and analyzed by BN-PAGE. As shown in Figure 2D, Tween® 20 was effective in converting the aggregate rich fraction to trimer (Figure 2D, left panel). Fractions of less purity containing HMW aggregate, dimers and monomers ( Figure 2D, right panel, - lane, each species denoted by arrows), when treated with Tween® 20 also resulted in collapse of HMW aggregate to resulting trimer ( Figure 2D, right panel, + lane).
- Size exclusion chromatography (SEC) analysis was performed as a second means to characterize the molecular sizes of KNHl 144 gpl20 monomer and SOSIP R6 gpl40 trimer proteins.
- a Superdex 200 size exclusion column was calibrated with thyroglobulin (669 kDa), ferritin (440 kDa), BSA (67 kDa) and RNAse A (13.7 kDa) as molecular weight standards.
- monomeric JR-FL gpl20 was also analyzed as a control. KNHl 144 gpl20 and JR-FL gpl20 were each found to migrate at an apparent molecular weight of 210 kDa. These values are consistent with those found for JR-FL gp!20 (10).
- trimer In order to maintain homogenous (rimers, treated trimer was resolved in the presence of TN-500 containing 0.05% Tween® 20 (TNT-500). As shown in Figure 3, ⁇ bottom panel BN-PAGE), the trimer ⁇ thick arrow) migrated from fractions BlO through C2, represented in the major peak, with its peak signal at fraction B12 ⁇ vertical arrow). The retention time at this fraction corresponds to an apparent calculated molecular weight of ⁇ 518 kDa.
- the reported apparent molecular weight (MW) of JR-FL SOSIP gpl40 trimer calculated via Superdex 200 SEC analysis is -520 kDa (9); and thus, the calculated apparent MW value for KNHl 144 SOSIP R6 gpl40 trimer is consistent with MW values of other SOSIP envelope trimers.
- Tween® 20 treatment and consequential conversion of HMW aggregate to resulting trimer enhances epitope exposure for Env binding antibodies.
- Tween® 20 treatment and presence may offer favorable consequences in the context of KNHl 144 SOSIP R6 gpl 40 trimer stability and antibody epitope exposure.
- Electron microscopy was performed on purified SOSIP R6 preparations employing negative stain EM analysis.
- the results, shown in Figure 6, reveal that the majority of the observed structures displayed a regular compact morphology with approximate three-fold symmetry. This tri-lobed configuration is most apparent in preparations with deeper stain ( Figure 6; panel of trimers) that are less subject to the flattening that can occur in thinner staining preparations.
- HIV-I £nv-based protein vaccines In the context of identifying and pursuing a variety of HIV-I £nv-based protein vaccines, described herein is the purification and characterizion of a novel subtype A KNHl 144 trimeric envelope spike protein and its properties.
- HIV-I JR-FL has been manipulated to a purified form to mimic as closely as possible the native trimeric structure of the HIV-I viral surface envelope complex via the SOSIP technology (8-11, 15-17).
- the present invention provides another clade, clade A KNHl 144, for which the SOSIP technology results in purified trimeric envelopes that are stable, soluble, and fully cleaved.
- the purification process implemented according to the present invention for the KNHl 144 SOSIP trimers provides a marked improvement over that utilized for JR-FL SOSIP gpl40 trimers.
- the GNA lectin column provided a significant enrichment of gpl40 proteins, but elution off the column significantly destabilized the gpl40 trimers, resulting in a compromise of trimer fidelity on the column. As a result, significant dissociation of the trimer to resulting dimer and monomer was noticed.
- This destabilization could be brought about from Galanthus Nivalis lectin binding to ⁇ l-3 and ⁇ l-6 mannose linkages on the gpl40 high mannose chains, which are internal linkages and not terminal linkages (20).
- the affinity of the lectin for the mannan is likely much higher than the intersubunit protein-protein affinities of the 3 gp!20-gp41 E c ⁇ o monomers contributing to trimer formation, resulting in destabilization and dissociation into component dimers and monomers.
- a one hour incubation in MMP eluting buffer was included. So while a highly enriching step, the lectin affinity column also decreased the final yield of trimer significantly, due to its dissociation during the elution phase.
- KNHl 144 SOSIP R6 g!40 trimer It is relevant to extrapolate from its behavior on anion exchange chromatography that the nature of the KNHl 144 SOSIP R6 g!40 trimer is that of an acidic protein, which would be contrary to its predicted basic isoelectric point (pi) of 8.73 calculated for the protein backbone. However, the likely presence of the predicted acidic sialylated complex oligosaccharide chains on the gpl40 (21, 22) would contribute to a decrease in the overall charge of the glycoprotein and thus confer on it properties of an acidic protein. Indeed, analysis of purified KNHl 144 SOSIP R6 gpl40 trimers on isoelectric focusing gels reveal it to migrate at a pi range of 5.9 to 6.1, consistent with the above observations.
- the purified trimer was shown to contain variable amounts of HMW aggregate (Figure 1, right panel, BN-PAGE), which could not be attributed to being formed at any one particular step of the purification, although one possibility might be at the lectin elution step.
- HMW aggregate Figure 1, right panel, BN-PAGE
- one of the key improvements made in this purification protocol is absence of SDS-insoluble aggregates in the final prep, which are formed by abberantly formed disulfide bonds and are visualized by their slow migration on a non-reduced SDS-PAGE.
- As detected by Coomassie staining and confirmed by anti-envelope Western blot little to no SDS-insoluble aggregates were observed (Figure 1, left and middle panels, Non-Red SDS-PAGE and Anti-Env blot). This is in contrast to what was observed with JR-FL SOSIP gpl40 (R6 and non-R6 versions), where SDS- insoluble aggregates comprised a significant percentage of the final preparations (9
- Tween® 20 was used to address the co-purifying HMW aggregate present in the final trimer preparations. Tween® 20 was chosen because initial observations had shown that Tween® 20 treatment was mild and did not result in any detectable monomer formation, unlike treatment with the other non-ionic detergents NP-40 and Triton X-IOO, where dinners and monomers were observed upon treatment (19). Tween® 20 treatment of the final purified KNHl 144 SOSIP R6 trimer preparation was highly reproducible and resulted in the "conversion" of the HMW aggregate species, as shown in Figure 1 (right panel, BN-PAGE).
- non-ionic detergents Since the nature of non-ionic detergents is exactly that, i.e., non-ionic, it is difficult to realize how an uncharged molecule such as Tween® 20 would affect the charge status of a large, macromolecular oligomer such as the KNHl 144 SOSIP R6 trimer. Furthermore, this effect is highly specific to the trimer, as other such large, highly charged (acidic) oligomeric proteins such as a ⁇ M and even smaller ones such as BSA are unaffected by the detergent.
- Tween® 20 was "coating" the trimer in a manner that may cause perturbations in its conformation, resulting in its "compactness".
- Tween® 20 and Tween® 80 are polyoxyethylene sorbitan esters of fatty acids and thus may likely interact with the sialic acids, causing a charge "neutralization” effect.
- the involvement of the sialic acid residues can be investigated by mild sialydase treatment (21, 22) and removal of these residues, followed by Tween® 20 treatment, followed by monitoring of binding on ion exchange resins.
- the predicted molecular weight for a trimer such as KNHl 144 (and JR-FL) would be -420 kDa (3 x 140 kDa monomers).
- the KNHl 144 SOSIP R6 gpl40 trimer also exhibits an abberant migration on SEC, presumably due to interactions of its ⁇ Minked glycans with the dextran- (agarose polymer) based matrix of Superdex 200, resulting in a higher than expected apparent molecular mass.
- envelope proteins have been shown to be non-globular in shape (10, 23, 24); therefore, gel filtration may not be optimal for determination of their precise molecular masses.
- Tween® 20 for KNHl 144 SOSIP R6 gpl40 proteins would be advantageous, possible Tween® 20 effects on the antigenicity of the HMW aggregate and trimer were examined. Effects on antigenicity was examined by performing lectin ELISAs with the NAbs 2G12, bl2, HIVIg, the CD4-IgG2 antibody conjugate PRO 542, as well as the non-neutralizing mAb b6, to gain information on neutralizing/non-neutralizing epitope exposure and accessibility- It was reasoned that trimer preparations containing 10-30% HMW aggregate may not undergo significant enough changes that would be detectable in a non-quantitative assay such as IPs, i.e., subtle changes (20-30% changes) may go undetected in such an assay due to sensititivity.
- IPs non-quantitative assay
- HIVIg which is a low neutralizing polyclonal human antisera directed against gpl20 hypervariable loop (40)
- HIVIg epitope is accessible on the surface of the HMW aggregate, based on its ability to bind the antibody in absence of Tween® 20.
- HIVIg epitope exposure also significantly increased on the rearranged trimer, upon treatment with Tween® 20.
- the likely explanation to these increases in epitope exposure is that "disruption/rearrangement" of the aggregate and its subsequent conversion to trimer unshields the above mentioned surfaces and thus, upon conversion, these surfaces are now exposed on their individual trimers and are accessible to the antibodies.
- KNHl 144 SOSIP R6 gpl40 proteins were indeed trimeric in nature ( Figure 6).
- the observation that the KNHl 144 SOSIP R6 trimer is compact is associated with anti-Env antibody epitope availability. EM on Tween®-treated trimer which has favorable anti-Env epitope exposure was performed.
- the present invention expands the panel of trimeric HTV-I envelope proteins that may be used as protein-based HIV-I vaccine candidates or serve as a template for future design of Env based protein vaccine candidates, using the SOSIP technology.
- the description of the KNHl 144 SOSIP R6 gpl40 trimers of the present invention addresses most of these issues. Furthermore, the description of the Tween® 20 affects on coverting HMW aggregates to trimeric forms further expands on current knowledge of the aggregate species in HIV-I biology. Of significance, it was shown for the first time, that oligomeric Env protein complexes designed using the SOSIP technology platform are indeed trimeric from EM images and that the trimers are of a similar diameter as native spikes on the HIV-I virion (36, 37).
- Expansion of the panel of potential HIV-I SOSIP protein vaccine candidates by development of a clade A envelope according to this invention now allows for immunological evaluation of the KNHl 144 SOSIP R6 gpl40 trimer in small animals, for example. Such evaluations will assist in S determining the efficacy of KNHl 144 SOSIP R6 gpl40 trimers as immunogens capable of eliciting broadly neutralizing immune responses directed against HIV-I.
- Subtype B 5768.4 SOSIP R6 gpl40 expression and purification The subtype B 5768.4 envelope sequence has been described (8). The sequence was modified to make the soluble SOSIP R6 gpl40 version, as described above for the KNHl 144 isolate in the section "Experimental Details I" and for the JR-FL SOSIP R6 gpl40 trimers (3, 4). DNA synthesis was performed by DNA 2.0 (Menlo Park, CA). The 5768.4 SOSIP R6 gpl40 trimer was expressed in HEK293 and small scale (2 L) purification was performed as described above for KNH 1 144 SOSIP R6 gp 140.
- Tween® 20 Dose effect: 1 ug of purified 5768.4 SOSIP R6 trimer was incubated with varying concentrations of Tween® 20 ranging from 0.1 to 0.0001% (v/v) and incubated for 1 hour at room temperature. Following incubation, samples were analyzed by BN-PAGE as described above.
- Detergent effect on 5768.4 SOSIP R6 gpJ40 trimer preparations 0.24 ug of purified 5768.4 SOSIP R6 trimer was incubated with Triton X-IOO, NP-40, or SDS to a final detergent concentration of 0.1% (v/v) or with Tween® 20 at concentrations of 0.05 and 0.1% for 1 hour at room temperature. Following incubation, 4x BN-PAGE MOPS sample buffer was added and the samples were immediately analyzed on BN-PAGE at 150 V for 2 hours at room temperature, followed by Coomassie G-250 staining.
- Detergent treatments were performed on a trimeric gpl40 of a different subtype 5768.4, which is a subtype B envelope (8).
- the 5768.4 Env protein was modified to the SOSIP R6 version, expressed and purified as a gpl40 trimer.
- the purified final preparation contained high HMW aggregate content ( ⁇ 60%) and minor a 2 M contamination ( ⁇ 5%), with trimer comprising the rest.
- Purified preparations were incubated with the various indicated detergents (Triton X-IOO, NP40, SDS, or Tween® 20) and were treated to collapse HWM aggregate.
- Tween® (Tween® 20 and Tween® 80) effectively collapsed HMW aggregate to trimers at 0.1 and 0.05% concentrations.
- Triton X-100 was also capable of collapsing HMW aggregate to trimer, however, some breakdown to monomeric 5768.4 was observed.
- SDS was effective in breaking down the entire 5768.4 gpl40 protein to resulting monomers by virtue of its denaturing effect on the trimer and HMW aggregate.
- NP40 treatment also led to collapse of HMW aggregate to trimer, but the resulting trimer displayed a somewhat broader staining compared with that of Tween® 20 treated trimers.
- the detergent effect, in particular, Tween® 20, on the HMW aggregate is not unique to KNHl 144 SOSIP gpl40 Env proteins and exhibits similar HMW aggregate collapse ability on other subtypes of HIV envelope trimers as well, such as the 5768.4 SOSIP R6 gpl40.
- An efficient purification process was developed to purify SOSlP Env trimers and to increase the yield of trimers. This process is exemplified by using a preparation, e.g., a cell culture fluid containing KNHl 144.R6 SOSIP proteins, to purify KNHl 144.R6 SOSIP trimers.
- a preparation e.g., a cell culture fluid containing KNHl 144.R6 SOSIP proteins
- CCF concentrated cell culture fluid
- MMP methyl-a-D- mannopyranoside
- the trimer-containing eluted fractions from the lectin chromatography column were applied to a first DEAE sepharose column (DEAE 1) in the absence of Tween 20®.
- a 5-ml HiTrap DEAE FF sepharose column (GE Healthcare/Amersham Biosciences Piscataway, NJ) was used in this step.
- the DEAE 1 chromatography was performed at room temperature.
- the column equilibration buffer comprised 20 mM Tris, 0.075 M NaCl, pH 8.0, and the column equilibration flow rate was 10 ml/min.
- the column loading and elution flow rate was 2.5 ml/min with a fraction size of 2.5 ml.
- the high flow rate allowed this step to be completed in a short amount of time.
- the KNH1 144.R6 gpHO trimer product was eluted from DEAE 1 in several fractions through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes (10 CV).
- KNHl 144 SOSIP.R6 gpl40 monomers and dimers were removed in the flow through and wash step using 20 mM Tris, 75 mM NaCl (pH 7.5) at room temperature.
- a second Hi-Trap DEAE FF sepharose column (DEAE 2) was equilibrated with buffer containing Tween 20® (20 mM Tris, 75 mM NaCl, 0.05% Tween, pH 8.0). The DEAE 2 chromatography was also performed .at room temperature.
- the DEAE 1 elution fractions containing KNHl 144 SOSTP .R6 trimers in buffer also containing Tween 20® was applied to the second DEAE column.
- the KNHl 144 SOSIP.R6 trimer product was obtained in the flow- though and in the wash pool, since KNHl 144 SOSIP.R6 trimer did not bind to the DEAE column in the presence of Tween 20® in the buffer.
- a suitable range of Tween 20Cg) for purification of the SOSIP.R6 trimers is 0.025% to 1%. 0.05% Tween 20® was used in many purification runs.
- the immunogenicity of the KNHl 144 SOSIP.R6 trimer product was also tested by immunoprecipitation (IP) experiments, e.g., as shown in Figure 13 using ARP 3119 probing antibody (also known as CA13) (MRC Centralized Facility for AIDS reagents, NIBSC, UK). 2G12, bl2, b6, and 15e are HTV neutralizing antibodies used in the IP experiment.
- PRO542 is a CD4-IgG2 heterotetrameric protein.
- 75 ug KNHl 144 SOSIP.R6 trimer was purified using this purification method from 1 liter (IL) of cell culture fluid (CCF).
- trimer product was recovered from IL of CCF using the purification method described in this example.
- the resulting purified and enriched trimer product was free from aggregates, monomers and dimers.
- Monomer content was less than 5% based on BN-PAGE/silver stain gel analysis.
Abstract
This invention provides processes of purifying and recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof. Non-ionic detergent is used in the processes to obtain a purified trimer product, which is separated from aggregates. The process further comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and purifying and recovering the trimers from the preparation so treated.
Description
Docket No. 76341 -A-PCT
Processes For Recovering Stabilized Formulations Of Trimers Of Retroviral Envelope (Env> Proteins
This invention was made with support under United States Government Grant Nos. AI 45463, Al 36082, and AI 30030 from the National Institutes of Health, and the Henry M. Jackson Foundation for the Advancement of Military Medicine under Cooperative Agreement Number DAMDl 7-98-2-8007 between the Foundation and the U.S. Army Medical Research Acquisition Activity (USAMRAA). Accordingly, the United States Government has certain rights in the subject invention.
Throughout this application, certain publications are referenced. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention relates.
BACKGROUND OF THE INVENTION
According to the 2005 World Health Organization AIDS epidemic update, there are over 40 million people infected with human immunodeficiency virus (HIV) worldwide, with close to 5 million newly infected cases reported just last year (1). Among one of the hardest hit areas is sub-Saharan Africa, with over 25 million people living with HIV and about 10% dying of AIDS- related illnesses. It has been widely recognized and accepted that prophylactic measures in the form of an HIV vaccine, in addition to therapeutic medicines, need to be implemented to curtail the spread of AIDS globally. An effective HIV vaccine should demonstrate an ability to elicit neutralizing antibodies (nAb) that are capable of blocking the fusogenic interaction and entry of HIV with the CD4 receptor on CD4+ helper T cells, mediated by the cell surface viral Env glycoproteins, gρl20 and gp41. Since the genetic polymorphism of the HTV-I gag and env genes are diverse and constantly evolving due to rapid mutation within individuals (2), the nAbs targeting the gpl20 and gp41 envelope proteins on the viral surface should be capable of blocking the viral interaction with the CD4 receptor and should neutralize viruses from a broad range of subtypes without discrimination.
One logical design of recombinant Env vaccine candidates is to base the vaccine sequence on currently existing HIV-I isolates prevalent in the infected population. To this end, several oligomeric env proteins from several different subtypes or "clades" have been described, with subtype B sequences serving as a basis for the majority of those that have been reported (3-11,
29, 31). The oligomeric Env protein complex on the surface of the virus is comprised of a gpl20-gp41 heterodimer present in a homotrimer configuration (held together via non-covalent interactions), resembling a "spike" structure. These glycoproteins are derived from a gpl 60 precursor protein, which undergoes processing and cleavage in the cell to generate gpl 20 and gp41 heterodimers that are then targeted to the surface of the HIV viral envelope (12, 13). Fusion of the virus with the CD4+ cell membrane and oligomerization of the trimer spike is mediated by the gp41 glycoprotein, which is tethered to the virion surface via its transmembrane domain (12, 13).
It has been reasoned that design of a recombinant vaccine should mimic the native trimer spike of the HIV envelope against which nAbs are generated. Since the native Env trimer is technically challenging to produce in a recombinant form, modified versions of the trimer that could serve as potential vaccine templates have been reported. One typical modification is truncation of the gp41 transmembrane domain from the precursor gpl 60 to yield gpl 40 proteins in a soluble form. However, following processing and cleavage, the resulting gpl20 and gp41 ectodomain or gp4lEcτo (lacking the transmembrane domain) have been shown to form unstable associations and tend to dissociate into their respective monomeric subunits (13, 14).
To address these issues, subtype B HIVJR.FL Env was used as a template into which a disulfide bond was introduced between gpl20-gp4lEcτo subunits (SOS gpl40), followed by a further modification to gp4lEcτo (I559P mutation), which successfully allowed for the expression of - stable, cleaved and fully processed oligomeric gpl 40 proteins in a trimeric conformation (SOSIP gpl40) (8-1 17 15-17). While immunization of rabbits performed with the engineered HIV-1JR.FL
SOSIP gpl40 elicited antibodies capable of neutralization, the activity was limited primarily to the homologous strain, with only a modest and limited ability to neutralize across different HIV-
1 primary isolates (11).
While the SOSIP technology addresses stability and expression, another issue that has limited production and purification of the recombinant trimers has been the spontaneous association of the oligomeric gpl40 proteins into abberant "aggregate" species (3, 9, 1 1, 18). These aggregate species, typically identified by their reduced mobility on blue native PAGE (BN-PAGE) and non-reduced SDS-PAGE have been difficult to purify from the SOSIP gpl 40 trimer without compromising yield and/or stability of the trimer. Attempts to fully characterize the aggregate have been limited and their true nature remains elusive.
To explore a wider variety of oligomeric Env proteins that elicit higher breadths of cross- neutralization activity and serve as potential vaccine immunogens, a panel of subtype A sequences from HIV-I primary isolates in sub-Saharan Africa was described (19). The Env proteins from these sequences were expressed as SOSIP gpl40 proteins, with a further engineered mutation at the gpl20-gp41ECτo cleavage site (R6) for enhanced furin cleavage (>95% efficiency) to yield soluble, stable and fully processed gpl40 trimers.
To address a need in the art for HIV Env proteins that may serve as stable immunogens and may mimic native HIV Env protein for the production of broadly reactive neutralizing antibodies, the present invention provides novel modified HIV-I Env protein isolates which are purified as complex trimeric forms that closely resemble the structural Env spikes of the native HIV envelope. A novel recovery process for obtaining trimeric Env gpl40 protein is also provided.
SUMMARY QF THE INVENTION
Described herein is the purification and biochemical characterization of HIV-I Env isolates, e.g. a modified subtype A KNHl 144 SOSIP R6 gpl40, derived from a contemporary East African subtype A HIV-I primary isolate, and a modified subtype B 5768.4 SOSIP R6 gpl40, using novel methodologies that are different from currently implemented purification procedures. The purified KNHl 144 SOSIP R6 gpl40 and 5768.4 SOSIP R6 gpl40 are trimers, as assessed by BN-PAGE and size exclusion chromatography (SEC). In addition, described herein are newly discovered effects of non- ionic detergents, such as Tween® 20, on aggregates of the KNHl 144 SOSIP R6 and the 5768.4 SOSIP R6 gpl40 proteins, thus providing insights into the nature of the aggregate species. The effects of Tween® 20 treatment on the antigenic properties of KNHl 144 SOSIP R6 gpl40 aggregates and trimers are described in accordance with the invention. New processes of purifying trimers (greater than 90% trimers) from high molecular weight aggregates of such trimers are provided in accordance with this invention. Finally, digital imaging based on negative stain electron microscopy reveals the structure of purified KNHl 144 SOSIP R6 gpl40 as trimeric oligomers in the virtual absence of monomeric and dimeric forms.
This invention provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereofs which comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation so treated.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises: (a) subjecting the preparation to lectin chromatography to obtain a trimer-enriched eluate in which aggregate content is reduced; (b) applying the eluate of step (a) to a first diethylaminoethyl (DEAE) sepharose chromatography column in the absence of non-ionic detergent to obtain elutioπ fractions further enriched in trimers; (c) applying trimer- enriched elution fractions from the first DEAE sepharose chromatography column of step (b) to a second DEAE sepharose chromatography column in the presence of non-ionic detergent; and (d) collecting the flow through and wash fractions from the second DEAE sepharose chromatography column in the presence of non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof, which comprises: (a) subjecting the preparation to lectin affinity chromatography to obtain an eluate enriched in trimers and essentially separated from monomer and dimer aggregates and macroglobulin; and (b) subjecting the eluate of step (a) to a first diethylaminoethyl sepharose chromatography column in the absence of πoπ-iσnic detergent so as to further remove aggregates in the flow through; and (c) subjecting the eluate of step (b) to a second diethylaminoethyl sepharose chromatography column in the presence of non-ionic detergent so as to recover the trimers of the retroviral Env protein.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which process comprises subjecting the preparation to size exclusion chromatography in the presence of a non-ionic detergent so as to convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation subjected to the chromatography.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to size exclusion chromatography to obtain eluted fractions; (b) subjecting the eluted fractions of step (a) to anion exchange chromatography; and (c) treating the fractions of step (b) with a non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain eluted fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent, so as to thereby recover the trimers of the Env protein.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions comprising monomers, dimers, and trimers of the Env protein; (b) subjecting the fractions of step (a) to size exclusion chromatography to obtain fractions comprising dimers and trimers of the Env protein; (c) subjecting the fractions of step (b) to anion exchange chromatography to obtain a fractions in which trimers of the Env protein are separated from dimers; and (d) treating the fractions of step (c) with non-ionic detergent, so as to thereby recover the trimers of the Env protein.
This invention also provides a process wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HTV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO.2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 511 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 617 and a proline at amino acid position 571, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO: 1, (ii) the modified gρl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 511 and the cysteine at amino acid position 617.
This invention further provides a process wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the
sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I 5768.4 isolate or such quasi- species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 625 and a proline at amino acid position 579, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:4, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 519 and the cysteine at amino acid position 625.
BRIEF DESCRIPTIONS OF THE FIGURES
FIGURE 1: Analysis of purified KNHl 144 SOSIP R6 gpl40 trimer and gpl20 monomer. Purified KNH 1144 gpl20 monomer (left panel, gp!20) and SOSIP R.6 gpl40 trimer were analyzed by reducing (left panel, SOSIP R6, Red) and non-reducing SDS-PAGE (left panel, SOSIP R6, NK). Proteins were visualized by Coomassie G-250 stain. Purified trimer was also analyzed via ARP31 19 western blot on non-reducing SDS-PAGE to examine presence of SDS- insoluble aggregates (middle panel, Anti-Env blot). The numbers on the left represent the migratory positions of the molecular weight standard proteins. The right panel shows BN-PAGE analysis of purified trimer, either untreated or treated with Tween® 20 (SOSIPR6, -/+ lanes) and purified gpl20 monomer in absence or presence of Tween® 20 treatment (gpl20, -/+ lanes). Arrows indicate high molecular weight (HMW) aggregate, trimer and gpl20 monomer species. A/ stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards.
FIGURES 2A-2D: Tween® 20 conversion experiments. (A) Dose response: Purified KNHl 144 SOSIP R6 gpl40 trimer was incubated with 0 (no detergent control), or 0.1, 0.05, 0.01, 0.001, or 0.0001% Tween® 20 and analyzed by BN-PAGE and Coomassie G-250 stain. Arrows point to HMW aggregate and trimer species. M stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards. (B) Time course: Purified KNHl 144 SOSIP R6 gpl40 trimer was incubated with Tween® 20 for 5 min (left panel) or 10 min (right panel). Trimer was either untreated (- lane) or Tween® 20 treated (+ lane). Arrows indicate trimer and
HMW aggregate bands. (C) Temperature effect: Purified KNHl 144 SOSIP R6 gpl40 trimer was either untreated (- lane) or treated with Tween® 20 at on ice (O)3 room temperature (RT) or 37°C. Reactions were analyzed by BN-PAGE and Coomassie G-250 stain. Arrows indicate HMW aggregate and trimer proteins. (D) Tween® 20 effect on HMW aggregate and dimer fractions: A preparation composed predominantly of HMW aggregate ( > 80%) was untreated (left panel, - lane), or incubated with Tween® 20 (left panel, + lane), and analyzed by BN-PAGE and Coomassie G-250 stain. Solid arrows indicate HMW aggregate and trimer proteins. Preparations composed of HMW aggregate, dimers and monomers were untreated (right panel, - lane) or incubated with Tween® 20 (right panel, + lane) and analyzed by BN-PAGE and Coomassie G-250 stain. Arrows on the right hand side point to aggregate, trimer, dimer and monomer species.
FIGURE 3: Size Exchange Chromatography (SEC) analysis of KNHl 144 SOSIP R6 gpl40 trimer. KNHl 144 SOSIP R6 gp!40 trimer was resolved on a Superdex 200 10/300 GL column in TN-500 buffer containing 0.05% Tween® 20 (TNT-500). The A28O protein profile of the run is shown in the middle panel. Fractions B7-C3 from the run were analyzed by BN-PAGE, followed by silver stain (bottom panel). Arrows to the side of the BN-PAGE image point to the trimer. The vertical arrow in the BN-PAGE indicates the peak signal of the trimer in fraction B 12. The arrow in the middle chromatograph corresponds to fraction B 12.
FIGURE 4: Effect of Tween® 20 treatment on KNHl 144 SOSIP R6 HMW aggregate antigenicity. Lectin ELISA of untreated and Tween® 20 treated KNHl 144 SOSIP R6 HMW aggregate: Untreated or Tween® 20-treated HMW aggregate were bound to GNA lectin coated ELISA plates and probed with 2Gl 2, b6, bl2, CD4-IgG2, and HIVIg. The panels represent their respective binding curves. Antibody affinity to the untreated HMW aggregate is represented by the curve having diamond lines. Affinity to the Tween® 20 treated HMW aggregate is represented by curve having square lines. The Y-axis represents the colorimetric signal at OD492 and the X-axis represents antibody concentration in [ug/ml]. Lectin ELISA of untreated and Tween® 20-treated KNHl 144 SOSIP R6 gpl40 trimer: Untreated or Tween® 20 treated trimer (containing 10-15% HMW aggregate) were bound to GNA lectin coated ELISA plates and probed with 2Gl 2, b6, bl2, and CD4-IgG2. The panels represent their respective binding curves. Antibody affinity to the untreated trimer is represented by the curve having diamond lines. Affinity to the Tween® 20 treated trimer is represented by the curve having square lines. The Y- axis represents the colorimetric signal at OD492 and the X-axis represents antibody concentration in [ug/ml].
FIGURE 5: Effect of Tween® 20 treatment on KNHI l 44 SOSIP R6 gpl40 trimer binding to DEAE anion exchange column. Purified KNHl 144 SOSIP R6 gpl40 trimer, spiked with alpha-2 macroglobulin (a2M) contaminant, was either untreated or treated with Tween® 20. Following treatment, sample was applied over an anion exchange column (DEAE HiTrap FF 1 ml column) (Load). Flow through (FT) fractions were collected and the column was washed (Wash). The column was eluted (Elution) and fractions were analyzed over BN-PAGE, followed by Coomassie G-250 stain. The top panel shows fractions analyzed from the untreated control trimer DEAE application. The bottom panel shows fractions analyzed from the Tween® 20 treated trimer DEAE application. Arrows point to trimer and a2M contaminant proteins. M stands for the 669k thyroglobulin and 440k ferritin molecular weight protein standards. Asterisks highlight the fraction where the trimer is found.
FIGURE 6: Negative stain electron micrographs of KNH 1144 SOSIP R6 gpl40 trimers. KNHl 144 SOSIP R6 gpl40 trimers were analyzed by negative stain electron microscopy. Bar = 50nm.
FIGURE 7: SEC analysis of KNHI l 44 gpl20 monomer: KNHl 144 gpl20 monomer was resolved on a Superdex 200 10/300 GL column in TN-500 buffer. The top chromatograph shows its A280 protein profile of the run. As a control, JR-FL gpl20 monomer was resolved in a similar manner and its A280 protein profile is displayed in the bottom chromatograph. The observed retention times for both monomers and their apparent calculated molecular weights are indicated.
FIGURE 8: Tween® 20 effect on a.M: Purified a2M was incubated with Tween® 20 (+ lane) or waa untreated (- lane). Reactions were analyzed by BN-PAGE and Coomassie stain. Arrow indicates a2M band.
FIGURE 9: Amino acid sequence (SEQ ID NO:1) of modified gpl40 the HIV-I KNHl 144 isolate.
FIGURE 10: Nucleic acid sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:4) of HΓV-1 5768.4 isolate.
FIGURES HA and HB: Gel analysis (A) BN-PAGE and (B) SDS-PAGE of purified trimer product using the purification method described in Experimental Details III
FIGURE 12: Gel analysis (BN-PAGE/Silver) of purified trimer using the purification method described in Experimental Details II (fifth lane) and using the purification method described in Experimental Details III (third lane). Molecular weight marker (first lane).
FIGURES 13A and 13B: Immunoprecipitation (IP) of KNHl 144 SOSIP.R6 using ARP3110 probing antibody (A) using the purification method described in Experimental Details III and (B) using the purification method described in Experimental Details II.
FIGURES 14A and 14B: Western Blot analysis of KNHl 144 SOSIP.R6 using ARP31 10 probing antibody (A) using the purification method described in Experimental Details III and (B) using the purification method described in Experimental Details II.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below.
The following standard abbreviations are used throughout the specification to indicate specific amino acids: A=ala=alanine; R=arg=arginine; N=asn=asparagine; D=asp=aspartic acid; C=:cys=cysteine; Q=gln=glutamine; E=glu=glutamic acid; G=gly=glycine; H=his=histidine; I=ile=isoleucine; L=leu=leucine; K=lys=lysine; M=met=methionine; F=phe=phenyla!anine; P=pro=proline; S=ser=serine; T=thr=threonine; W=trp:=tryptophan; Y=tyr=tyrosine;
or glutamic acid.
An "A5I 1C mutation" refers to a point mutation of amino acid 51 1 in the HIV-I KNHl 144 isolate gpl20 from alanine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 51 1 in all other HTV isolates. For example, in HIV-IJR.FL the corresponding amino acid is A492 (Genbank Accession No. U63632), in HIV-1HXB2 the corresponding amino acid is A501 (Genbank Accession No. AAB50262) and in HIV-lNL4-3 it is A499 (Genbank Accession No. AAA44992). The amino acid may also be an amino acid other than alanine which has similar polarity or charge characteristics, for example. This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art. This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
"157 IP" refers to a point mutation wherein the isoleucine residue at position 571 of a polypeptide chain is replaced by a proline residue.
A "T617C mutation" refers to a point mutation of amino acid 617 in HTV-I KNHl 144 isolate gp41 ectodomain from threonine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 617 in all other HIV isolates. For example, in HJV-I JR.FL the corresponding amino acid is T596 (Genbank Accession No. U63632), in HIV-I HXB2 the corresponding amino acid is T605 (Genbank Accession No. AAB50262) and in HIV-1NL4-3 the corresponding amino acid is T603 (Genbank Accesion No. AAA44992). The amino acid may also be an amino acid other than threonine which has similar polarity or charge characteristics, for example. This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art. This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
An "A519C mutation" refers to a point mutation of amino acid 519 in HIV-I 5768.4 isolate gp!20 from alanine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 519 in all other HIV isolates. For example, in HIV-IJR.FL the corresponding amino acid is A492 (Genbank Accession No. U63632), in HIV-1 HXB2 the corresponding amino acid is A501 (Genbank Accession No. AAB50262) and in HIV-1NL4.3 it is A499 (Genbank Accession No. AAA44992). The amino acid may also be an amino acid other than alanine which has similar polarity or charge characteristics, for example. This invention encompasses cysteine mutations in such amino acids, which can be readily identified in other HIV isolates by those skilled in the art. This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
"I579P" refers to a point mutation wherein the isoleucine residue at position 579 of a polypeptide chain is replaced by a proline residue.
A "T625C mutation" refers to a point mutation of amino acid 625 in HIV-I 5768.4 isolate gp41 ectodomain from threonine to cysteine. Because of sequence and sequence numbering variability among different HIV strains and isolates, it will be appreciated that this amino acid will not be at position 625 in all other HIV isolates. For example, in HIV-IJR-FL the corresponding amino acid is T596 (Genbank Accession No. U63632), in HIV-] HXB2 the corresponding amino acid is T605
(Genbank Accession No. AAB50262) and in HIV-INL-U the corresponding amino acid is T603 (Genbank Accesion No. AAA44992). The amino acid may also be an amino acid other than threonine which has similar polarity or charge characteristics, for example. This invention encompasses the replacement of such amino acids by cysteine, as may be readily identified in other HIV isolates by those skilled in the art.
"HIV" refers to the human immunodeficiency virus. HIV shall include, without limitation, HIV- 1. The human immunodeficiency virus (HIV) may be either of the two known types of HIV (HIV-I or HrV-2). The HTV-I virus may represent any of the known major subtypes (Classes A, B, C, D E, F, G and H) or outlying subtype (Group O).
"gpl40 envelope" refers to a protein having two disulfide-linked polypeptide chains, the first chain comprising the amino acid sequence of the HIV gpl20 glycoprotein and the second chain comprising the amino acid sequence of the water-soluble portion of HIV gp41 glycoprotein ("gp41 portion"). HIV gpl40 protein includes, without limitation, proteins wherein the gp41 portion comprises a point mutation such as I579P. gpl40 envelope comprising such mutation is also referred to as "HIV SOS gpl40", as well as "HIV gpRO monomer" or "SOSEP gpl40".
"gp41" includes, without limitation, (a) whole gp41 including the transmembrane and cytoplasmic domains; (b) gp41 ectodomain (gp4lEcτo); (c) gp41 modified by deletion or insertion of one or more glycosylation sites; (d) gp41 modified so as to eliminate or mask the well-known immunodominant epitope; (e) a gp41 fusion protein; and (f) gp41 labeled with an affinity ligand or other detectable marker. As used herein, "ectodomain" means the extracellular region of a transmembrane protein exclusive of the transmembrane spanning and cytoplasmic regions.
Embodiments of the Invention
This invention provides a process of recovering trimers of a retroviral envelope (Eπv) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation so treated. In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
In one embodiment, the above process further comprises formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises: (a) subjecting the preparation to lectin chromatography to obtain a trimer-enriched eJuate in which aggregate content is reduced; (b) applying the eluate of step (a) to a first diethylaminoethyl (DEAE) sepharose chromatography column in the absence of non-ionic detergent to obtain elution fractions further enriched in trimers; (c) applying trimer- enriched elution fractions from the first DEAE sepharose chromatography column of step (b) to a second DEAE sepharose chromatography column in the presence of non-ionic detergent; and (d) collecting the flow through and wash fractions from the second DEAE sepharose chromatography column in the presence of non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein. In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
In one embodiment of the above process, in step (a), the preparation is a concentrated cell culture fluid. In another embodiment, in step (a), the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography. In another embodiment, in step (a), column fractions enriched in trimers are eluted through a linear gradient in PBS to 1.0 M methyl-a-D- mannopyranoside (MMP) in ten column volumes. In yet another embodiment, in step (b), fractions further enriched in trimers are eluted from the DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes. In one embodiment, in step (c), the fractions further enriched in trimers are eluted from the second DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes. In one embodiment, the wash fractions of step (d) comprise buffer which comprises 20 mM Tris and 75 mM NaCl, pH 7.5.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof, which comprises: (a) subjecting the preparation to lectin affinity chromatography to obtain an eluate enriched in trimers and essentially separated from monomer and dimer aggregates and macroglobulin; and (b) subjecting the eluate of step (a) to a first diethylaminoethyl sepharose chromatography column in the absence of non-ionic detergent so as
to further remove aggregates in the flow through; and (c) subjecting the eluate of step (b) to a second diethylaminoethyl sepharose chromatography column in the presence of non-ionic detergent so as to recover the trimers of the retroviral Env protein. In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
In one embodiment of the above process, in step (a), the preparation is a concentrated cell culture fluid. In another embodiment, in step (a), the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography. In yet another embodiment, the trimers are recovered in the presence of the non-ionic detergent so as to maintain trimer stability upon subsequent storage. In one embodiment, the non-ionic detergent is a polyethylene type detergent. In another embodiment, the polyethylene type detergent is a poly(oxyethylene) sorbitan monolaureate. In another embodiment, the poly(oxyethylene) sorbitan monolaureate is poly (oxyethylene) (20) sorbitan monolaureate. In one embodiment, the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype A isolate is KNHl 144.
In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype B isolate is 5768.4. In another embodiment of the above process, steps (a) through (d) are carried out at room temperature. In one embodiment, steps (a) through (c) are carried out at room temperature. In one embodiment, the non-ionic detergent present is at a concentration of 0.001% to 1% by weight of the preparation. In another embodiment, the concentration of the non-ionic detergent is from 0.01% to 1% by weight. In one embodiment, the concentration of the non-ionic detergent is from 0.025% to 1% by weight. In another embodiment, the concentration of the non-ionic detergent is from 0.01% to 0.5% by weight. In another embodiment, the concentration of the non-ionic detergent is from 0.01% to 0.1% by weight. In one embodiment, the concentration of the non-ionic detergent is from 0.01% to 0.05% by weight. In another embodiment, the concentration of the non-ionic detergent is 0.05% by weight.
14
In one embodiment of the above process, prior to treatment with the non-ionic detergent, the preparation comprises greater than 10% high molecular weight aggregates. In another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises 10-40% high molecular weight aggregates. In yet another embodiment, prior to treatment with the non- ionic detergent the preparation comprises greater than 70% high molecular weight aggregates, the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO:2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 511 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 617 and a proline at amino acid position 571, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO: 1, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated fϊirin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 511 and the cysteine at am ino acid position 617.
In one embodiment, the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HW-I 5768.4 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 625 and a proline at amino acid position 579, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:4, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the
modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 519 and the cysteine at amino acid position 625. In one embodiment, the recovering further comprises purifying the trimers. In one embodiment, at least 50 μg of trimers are recovered from the preparation. In another embodiment, the above process further comprises formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
In the above-described trimer purification methods/processes, at least 50 μg of trimers are recovered from the starting preparation. In an embodiment, the above processes further comprise formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises subjecting the preparation to size exclusion chromatography in the presence of a non-ionic detergent so as to convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation subjected to the chromatography. In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
In one embodiment, the process comprises subjecting the preparation to size exclusion chromatography, and then subjecting the resulting preparation to anion exchange chromatography before recovering the trimers.
In another embodiment, the processes of the invention provide trimers which are recovered in the presence of non-ionic detergent so as to maintain trimer stability upon subsequent storage. The trimers in non-ionic detergent according to this invention are stable for days, weeks and months, e.g., greater than one week, greater than two weeks, greater than one month, greater than two months, or greater than six months to years, for example, ~4°C-25°C, at room temperature (~16°C-25°C), or frozen. In one embodiment, the non-ionic detergent is a polyethylene type detergent. In one embodiment, the polyethylene type detergent is a poly (oxyethylene) sorbitan monolaureate. In another embodiment, the poly (oxyethylene) sorbitan monolaureate is poly (oxyethylene) sorbitan monolaureate. In yet another embodiment, the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate, a mutant derived therefrom, or a quasi-species thereof. In another embodiment, the HIV-I subtype A isolate is KNHl 144.
In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate, a mutant derived therefrom, or a quasi-species thereof. In another embodiment, the HIV-I subtype B isolate is 5768.4.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to size exclusion chromatography to obtain eluted fractions; (b ) subjecting the fractions of step (a) to anion exchange chromatography; and (c) treating the column fractions of step (b) with a non-ionic detergent, so as to thereby recover the trimers of the Env protein. In one embodiment, the process further comprises re-subjecting the column fractions of step (b) to anion exchange chromatography prior to step (c). In another embodiment, approximately 30-40% more trimers are recovered following re-subjecting the fractions of step (b) to anion exchange chromatography. In another embodiment, the process further comprises re-subjecting the fractions of step (c) to anion exchange chromatography (e.g., DEAE anion exchange chromatography) to remove non-aggregate contaminants. In another embodiment, the size exclusion chromatography of step (a) is performed in the presence of a non-ionic detergent. In another embodiment, the retroviral Env protein is an HIV Env protein. In yet another embodiment, the retroviral Env protein is an HlV-I or HIV-2 Env protein.
This invention also provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain elution fractions; and (b) subjecting the fractions of step (a) to size exclusion chromatography in the presence of a non-ionic detergent so as to thereby recover the trimers of the Env protein.
This invention further provides a process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight
aggregates thereof which comprises (a) subjecting the preparation to lectin affinity chromatography to obtain fractions comprising monomers, dimers, and trimers of the Env protein; (b) subjecting the fractions of step (a) to size exclusion chromatography to obtain fractions comprising dimers and trimers of the Env protein; (c) subjecting the fractions of step (b) to anion exchange chromatography to obtain fractions in which trimers of the Env protein are separated from dimers; and (d) treating trimer-containing fractions of step (c) with non-ionic detergent, so as to thereby recover the trimers of the Env proteins. In one embodiment, the non- ionic detergent is a polyethylene type detergent. In another embodiment, the polyethylene type detergent is poly (oxyethylene) sorbitan monolaureate. In yet another embodiment, the poly (oxyethylene) sorbitan monolaureate is poly (oxyethylene) (20) sorbitan monolaureate. In another embodiment, the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
In one embodiment, the process further comprises re-subjecting the fractions of step (c) to anion exchange chromatography following step (c) and prior to step (d). In another embodiment, approximately 30-40% more trimers are recovered following re-subjecting the fractions of step (c) to anion exchange chromatography.
In yet another embodiment, the process further comprises re-subjecting the fractions of step (d) to anion exchange chromatography to remove non-aggregate contaminants. In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein.
In one embodiment of the processes of the invention, prior to treatment with the non-ionic detergent, the preparation comprises greater than 10% high molecular weight aggregates. In another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises 10-40% high molecular weight aggregates. In yet another embodiment, prior to treatment with the non-ionic detergent, the preparation comprises greater than 70% high molecular weight aggregates.
In one embodiment of the processes of the invention, the non-ionic detergent is present at a concentration of between 0.001% to 1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.01% to 1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.025% to 1% by weight of the preparation. In yet another embodiment, the concentration of non-ionic detergent is from 0.01% to 0.5% by weight of the preparation. In a further embodiment, the concentration of non-
ionic detergent is from 0.01% to 0.1% by weight of the preparation. In another embodiment, the concentration of non-ionic detergent is from 0.01% to 0.05%. In yet another embodiment, the concentration of non-ionic detergent is 0.05%.
In one embodiment, the retroviral Env protein is an HIV Env protein. In another embodiment, the retroviral Env protein is an HIV-I or HIV-2 Env protein. In one embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype A isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype A isolate is KNHl 144. In another embodiment, the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate or a mutant derived therefrom. In one embodiment, the HIV-I subtype B isolate is 5768.4.
This invention also provides processes described above, which further comprise formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
This invention also provides a process wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gρl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO:2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 511 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 617 and a proline at amino acid position 571, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:1, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gp!20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 51 1 and the cysteine at amino acid position 617. In one embodiment, the cysteine at position 51 1 is the result of an A51 1C mutation. In another embodiment, the cysteine at position 617 is the result of a T617C mutation. In yet another embodiment, the proline at position 571 is the result of an I571P mutation.
This invention further provides a process wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HTV-I S768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I 5768.4 isolate or such quasi- species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 625 and a proline at amino acid position 579, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:4, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 519 and the cysteine at amino acid position 625. In one embodiment, the cysteine at position 519 is the result of ah A519C mutation. In another embodiment, the cysteine at position 625 is the result of a T625C mutation. In yet another embodiment, the proline at position 579 is the result of an I579P mutation. In one embodiment, the process further comprises purifying the trimers so recovered.
This invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to limit in any way the invention as set forth in the claims which follow thereafter.
EXPERIMENTAL DETAILS I
INTRODUCTION
The present invention as described herein encompasses the purification and biochemical characterization of a KNHl 144 SOSIP R6 gpl40, derived from a contemporary East African subtype A HIV-I primary isolate, using novel methodologies that are different from previously implemented purification procedures. The purified KNHl 144 SOSIP R6 gpl40 is a trimer based on BN-PAGE and size exclusion chromatography (SEC) analyses. The present invention is directed to novel methods involving the use of non-ionic detergents, such as Tween® 20, to recover homogeneous trimeric forms of the KNHl 144 SOSIP R6 Env gpl40 protein from aggregates thereof. Trimers are recovered (also termed "collapsed" or "converted") from
aggregrates (of monomers, dimers and trimers) at greater than 90-98% purity, typically 100% purity using non-ionic detergent in accordance with this invention. The present invention also provides novel insights into the nature of the aggregate species. The effects of non-ionic detergent, e.g., Tween® 20, treatment on the antigenic properties of KNHl 144 SOSIP R6 gpl40 aggregates and trimers were examined. Finally, digital imaging based on negative stain electron microscopy was perform and reveals the structure of purified KNHl 144 SOSIP R6 gpl40 as trimeric oligomers.
Additionally, as described hereinbelow, the present invention is further directed to novel methods involving the use of non-ionic detergents, such as Tween® 20, to recover homogeneous trimeric forms of the subtype B 5768.4 SOSIP R6 Env gpl40 protein from aggregates thereof. Trimers are recovered (also termed "collapsed") from aggregates at greater than 90-98% purity, typically 100% purity using non-ionic detergent.
MATERIALS AND METHODS
Subtype A KNHl 144 SOSIP R6 transfection and expression:
The KNHl 144 SOSIP R6 envelope and furin DNA plasm ids were as described. For a typical 8 L preparation, HEK 293T cells were seeded in triple flasks at a density of 2.5 x 107 cells/flask and cultured in DMEM/10% FBS/1% pen-strep with 1% L-glutarnine 24 hours prior to transfection. On the day of transfection, 270 ug of KNHl 144 SOSIP R6 envelope DNA was mixed with 90 ug of Furin protease DNA plasmid (per flask) in Opti-MEM. Polyethyleneimine (PEI) was added stepwise (2 mg PEI: 1 mg total DNA) and vortexed immediately in between each addition. The PEI/DNA complex solutions were incubated for 20 minutes at room temperature. Complexes were then added to the flasks and incubated for 6 hours at 32°C, 5% CO∑. The cells were then washed with warmed PBS and then incubated in exchange media (DMEM/ 0.05% BSA/1% pen-strep) for 48 hours at 32°C, 5% CO2. After the 48 hour incubation, the supernatants were collected and a cocktail of protease inhibitors was added to minimize protein degradation. Harvested supernatants were then clarified by filtration through a 0.45um filter and concentrated to 53X. Expression of KNHl 144 gpl20 monomer has been previously described (1 ) and typically, 1-2 L of cell culture supernatants from transfected cells were harvested. Supernatants were clarified by filtration and stored at -8O0C without any concentration prior to purification.
Purification of KNHl 144 SOSIP R6 f_pl40 and gpl20:
KNHl 144 SOSIP R6 gpl40 trimer was purified via a four step process starting with an ammonium sulfate precipitation followed by lectin affinity, size exclusion and ion-exchange chromatography. 53X concentrated cell culture supernatant was precipitated with an equal volume of 3.8 M ammonium sulfate to remove contaminant proteins (with the major contaminant being α-2-macroglobulin). The ammonium sulfate was added with constant stirring with a stir bar and then was immediately centrifuged at 4000 rpm, 4°C for 45 minutes. The resulting supernatant was diluted 4-fold with PBS, pH 7.25, and was filtered using a 0.45 urn vacuum filter. The sample was then loaded at 0.5-0.8 ml/min onto a Galanthus nivalis (GNA) lectin (Vector Laboratories, Burlingame, CA) column equilibrated with PBS- pH 7.25. Once the load was finished, the column was washed with PBS pH 7.25 until OD2βo reached baseline, followed by a second wash with 0.5 M NaCl PBS pH 7.25 at 1 ml/min in order to remove contaminant proteins (mainly BSA). The column was then eluted with 1 M MMP PBS pH 7.25 starting with flowing one half CV through the column at 0.3 ml/min and pausing the purification for a 1 hour incubation in MMP elution buffer. Following the incubation, the flow was restarted at 0.3 ml/min and 0.5-1 ml fractions were collected. All peak fractions were then pooled and concentrated to a final volume of 1 ml using a Vivaspin 100,000 MWCO concentrator (Vivascience, Edgewood, NY) centrifuged at 1000 x g. The concentrated lectin elution was applied over a Superdex 200 SEC column (GE Healthcare, Piscataway, NJ) equilibrated in 20 mM Tris pH 8, 200 mM NaCl (TN-200), injecting 0.5 ml of sample per run and was resolved at 0.4 ml/min, collecting 0.4 ml fractions. The fractions were analyzed by BN-PAGE using a 4- 12% Bis-Tris NuPAGE gel (Invϊtrogen, Carlsbad, CA) ( 10). All trimer containing fractions were pooled and diluted to 75 mM NaCl with 2OmM Tris pH 8. The diluted SEC pool was then applied over a 1 ml HiTrap DEAE FF column (GE Healthcare), equilibrated in 20 mM Tris pH 8, 75 mM NaCl (TN-75). The diluted SEC pool was loaded at 0.5 ml/min. The column was washed with TN-75 at 1 ml/min until the OD280 reached baseline. The column was then eluted with 20 mM Tris, 300 mM NaCl pH 8 at 1 ml/min, collecting 0.5 ml fractions.
To maximize trimer yield, the flow-through fraction from the DEAE column was re-applied over the column (equilibrated in TN-75) and typically 20-30% or 30-40% more trimer was recovered in this manner. The fractions were analyzed by BN-PAGE and by reducing and non-reducing
SDS-PAGE. Western blot analysis on non-reduced SDS-PAGE gel was performed with the
ARP31 19 monoclonal antibody. The trimer containing fractions were pooled and trimer concentration was determined through densitometry on a reducing SDS-PAGE gel using IR-FL gp 120 as a standard .
KNHl 144 gpl20 monomer:
Unconcentrated cell culture supernatants containing secreted gpl20 monomer were applied directly over a GNA lectin column equilibrated in 20 mM imidazole pH 7.1 at 1-2 ml/min. Following adsorption, the column was washed with a high salt (PBS containing 1 M "NaCl, pH 7.1) wash, followed by a low salt (20 mM imidazole pH 7.1) wash. The column was eluted with 1 M MMP in 20 mM imidazole, 0.2 M NaCl pH 7.1. Peak fractions were pooled and diluted with 20 mM imidazole, pH 7.1, thirteen-fold to a final buffer concentration of 20 mM imidazole, pH 7.1, 15 mM NaCl. The diluted GNA elution was applied over 1 ml HiTrap Q Sepharose FF (GE Healthcare) equilibrated in 20 mM imidazole, pH 7.1. Following binding, the column was washed with 20 mM imidazole, pH 7.1, and was eluted with 20 mM imidazole, 0.2 M NaCl, pH 7.1. The Q elutions were pooled and concentrated and applied over a Superdex 200 column equilibrated in PBS in 0.5 ml volumes and resolved at 0.4 ml/min. Peak fractions were analyzed by 4-12% Bis-tris gels (Invitrogen), followed by Coomassie staining. Fractions containing gpl20 were pooled and quantified as described above for the SOSIP R.6 gpl40 trimers and stored at -800C.
Tween® 20 Aggregate "conversion"/"collapse" experiments:
Tween® 20 Dose effect: 1 ug of purified KNHl 144 SOSIP R6 trimer was incubated with varying concentrations of Tween® 20 (polyoxyethylene sorbitan monolaurate) ranging from 0 to 0.0001 % (v/v) and incubated for 1 hour at room temperature. Following incubation, samples were analyzed by BN-PAGE as described above.
Kinetics of Tween® 20 effect: To ascertain the early kinetics of the Tween® 20 effect on aggregate, 1 ug of purified KNHl 144 SOSIP R6 trimer was incubated with Tween® 20 at a final concentration of 0.05 % (v/v) for 5 minutes and for 10 minutes. A no-detergent control was included separately for each timepoint.
Temperature dependance on Tween® 20 effect: To determine if temperature affected the ability of Tween® 20 to recover trimers from aggregates (i.e., collapse aggregate into trimer), 1 ug of purified KNHl 144 SOSIP R6 trimer was incubated with Tween® 20 to a final concentration of 0.05% (v/v) at 00C (on ice), room temperature (22-23°C) at 37°C, or left untreated for 10 minutes. Following the incubation, samples were analyzed by BN-PAGE and Coomassie staining.
Tween® 20 effect on KNHl 144 gpl20: To test if Tween® 20 had a similar effect on KNHl 144 gpl20, 1 ug of purified gpl20 monomer was either untreated or incubated with Tween® 20 at a final concentration of 0.05% for 10 minutes at room temperature. Following the treatment, samples were analyzed by BN-PAGE and Coomassie staining.
Tween® 20 effect on a-2-macroglogulin (a2M): 0.5 ug of purified α-2-macroglobuHn was either untreated or treated with Tween® 20 at a final concentration of 0.05% for 10 minutes at room temperature. Reactions were analyzed via BN-PAGE, followed by Coomassie staining.
Size exclusion chromatography CSEO analysis:
All runs were performed at 4°C on the AKTA FPLC system (GE Healthcare). Each run was performed at least twice.
Molecular weight standards SEC: A Superdex 200 10/300 GL column was equilibrated in 20 mM Tris pH 8, 0.5 M NaCl (TN-500) and calibrated with the following molecular weight standard proteins: thyroglobulin 669,000 Da; ferritin 440,000 Da; BSA 67,000 Da; and RNAse A 13,700 Da. A standard curve was generated by plotting the observed retention volumes of the standard proteins against the log values of their predicted molecular weights.
KNHl 144 gp!20 SEC analysis: 14 ug of purified KNH 1144 gp 120 (either untreated or Tween® 20-treated as described above) was applied over the Superdex 200 column equilibrated in TN- 500 and resolved at a flow rate of 0.4 ml/min. As a control, 10-14 ug of JR-FL gpl20 was also analyzed in a similar manner.
KNHl 144 SOSIP R6 gpUO SEC analysis: 8-10 ug of purified KNHl 144 SOSIP R6 gpl40 was treated with Tween® 20 at a final concentration of 0.05% for 10-30 minutes at room temperature. Treated samples were then applied over the Superdex 200 column equilibrated with TN-500 containing 0.05% Tween® 20 (TNT-500) and resolved at 0.4 ml/min, collecting 0.4 ml fractions. Trimer-containing fractions were then analyzed by BN-PAGE, followed by silver staining. Fractions were also separated by BN-PAGE, followed by Western blot analysis with ARP 3119 antibody.
Blue Native PAGE fBN-PAGE) and SDS-PAGE analysis:
All SDS-PAGE analysis (reduced and non-reduced) were performed using 4-12% Bis-Tris NuPage gels (Invitrogen). BN-PAGE analysis was performed as described (10). Silver stain
analysis was performed with the SilverQuest kit (Invitrogen). Coomassie G-250 stain was performed using either the SimplyBlue SafeStain or Easy-to-Use Coomassie® G-250 Stain (Invitrogen).
Antigenicity Experiments - Lectin ELISA:
Human mAbs b6 (32), bl2 (33) and 2Gl 2 (26), HIVIg (40) were obtained from Dr. Dennis Burton (The Scripps Research Institute, La JoIIa3 CA) or Dr. Herman Katinger (University of Natural Resources and Applied Life Sciences, Austria, Vienna). For the lectin based ELISA, anti-Env antibodies 2G12, b6, bl2 and HIVIg were used. In addition, the CD4-IgG2 antibody conj ugate PRO 542 (39) was also used .
ELISA plates were coated overnight at 4°C with lentil lectin powder from Lens culinaris (L9267, Sigma) at 10 ug/ml concentration. Plates were washed with PBS twice and blocked with SuperBlock (Pierce) (warmed to RT). Excess blocking agent was washed off with PBS. SEC fractions containing HMW aggregate were either untreated or treated with 0.05% Tween® 20 (v/v, final concentration) for 30 minutes at room temperature (RT) and were added at 0.3 ug/ml (diluted in PBS) and bound to the plates (via the lectin) for 4 hours at RT. Following binding, plates were washed 4 times with PBS and incubated with primary anti-Env antibodies starting at 10 ug/ml in PBS/5% milk. 4x serial dilutions were performed and incubations were performed for 3 hours at RT. Following antibody incubation, plates were washed 6 times and goat anti- human IgG (H+L) alkaline phosphatase conjugate secondary antibody (Jackson ImmunoResearch) was added at 1/4000 concentration in PBS/5% milk. Plates were washed 4 times and ELISAs were developed using the Ampak detection system (Dako Cytomation, Carpinteria, CA) as per the manufacturer's instructions.
DEAE anion exchange chromatography of Tween® 20-treated KNHl 144 SOSIP R6 epl40 trimers:
Purified KNH 1144 SOSIP R6 gpl40 trimers, treated either with or without 0.05% Tween® 20
(final), containing a2M contaminant in TN-75 buffer was applied over 1 ml DEAE HiTrap FF column (equilibrated in TN-75) at 0.25 ml/min at RT and flow-through (FT) fractions were collected. Following sample loading, the column was washed with TN-75 at 0.5 ml/min and wash fractions were collected. Finally, the column was eluted with TN-300 and equal amounts from each fraction were analyzed via BN-PAGE, followed by Coomassie G-250 staining.
Electron microscopy:
EM analysis of the SOSIP trimers was performed by negative stain as previously described (34, 35). Because this technique is incompatible with detergent, 20 μl of the original sample (0.5 mg/ml in TN-300) was dialyzed against BSB (0.1 M H3BO3, 0.025 M Na2B4O7, 0.075 M NaCl, pH 8.3) and subsequently depleted of detergent using the Mini Detergent-OUT™ detergent removal kit (Calbiochem, La JoIIa, CA) as described by the manufacturer. Two microliters of the resulting protein solution, diluted in 200 μl BSB, was affixed to carbon support membrane, stained with 1% uranyl formate, and mounted on 600 mesh copper grids for analysis. EMs were recorded at XlOO5OOO at 100 kV on a JOEL JEM 1200 electron microscope. Measurements were made using the Image-Pro Plus software program. Fifty or more trimers were measured and analyzed statistically. The average diameter of the compact trimers formed by the SOSIP gpl40 (e.g., KNHl 144.R6 SOSIP) proteins was about 12-13 nm.
RESULTS Expression and Purification of Trimeric KNHl 144 SOSIP R6 gpl40:
The purification of KNHl 144 SOSIP R6 gpl40 trimers typically involved three chromatography steps: GNA lectin affinity, Superdex 200 size exclusion and DEAE weak anion exchange. 53X concentrated cell culture supernatant precipitated with ammonium sulfate was clarified by centrifugation, diluted and applied over the GNA lectin affinity column to capture gpl40 proteins via (α-1, 3) mannose residues. Analysis of the ammonium sulfate precipitation using different starting concentrations of harvested cell culture supernatant (10OX to 40X) revealed that 53X was the optimum condition at which maximum α-2-macroglobulin precipitated out, with minimal envelope protein loss. While the GNA lectin column was highly efficient in capture of the gpl40 trimer, elution of the protein under even extremely mild conditions, with the competing MMP eluant, caused significant de-stabilization of the trimer and resulted in marked dissociation of the trimer into dimer and monomer species. . Attempts to separate the different oligomeric gpl40 species via Superdex SEC resulted in efficient separation of the monomer from the dimer and trimer. Superdex 200 SEC of the GNA eluate yielded trimers that were free of monomers, but not of dimers. To resolve trimers away from dimers (and residually co-migrating monomers), a DEAE anion exchange step was incorporated, which led to very efficient separation of dimer from trimer, thereby yielding pure trimers at the end of the purification protocol.
SDS-PAGE analysis under reducing conditions showed that the final preparation was of high purity (at least 90%), with only the gpl20 moiety visible on the reduced gel (Figure 1, left panel, center lane). Common serum contaminants that were detectable by reducing SDS-PAGE were α-
2-macroglobulin (a2M) and BSA, which typically comprised up to -10% of the final preparation. The non-reduced gel shows intact gpl40 protein on SDS-PAGE (Figure 1 , left panel, right lane). In addition, little to no disuifide-linked aggregate (typically revealed as migrating much slower on a non-reducing gel) was detected. This was confirmed by anti-envelope Western blot analysis on the non-reduced gel (Figure 1, Anti-Env blot, middle panel). BN-PAGE analysis of the purified trimer revealed the purified trimer to migrate between the 669k thyroglobulin and 440k ferritin marker proteins (Figure 1, right panel, SOSIP R6). This is consistent with the migration patterns for JR-FL SOSIP gp!40 which has been observed to migrate in the lower range of 669k and 44OkDa (9, 10, 11). An additional slower migrating band, typically classified as high molecular weight (HMW) SOSIP aggregates and comprising about 30% of the preparation, was also detected (Figure 1, right panel, SOSIP R6, - lane). Typical HMW aggregate content ranged from 10 to 40% of the final preparation prior to non-ionic detergent treatment. Treatment of the purified preparation with Tween® 20 at a final concentration of 0.05% converted the HMW aggregate species to trimers, yielding a homogenous trimer preparation (Figure 1, right panel, SOSIP R6, + lane)(19). It should be noted that treatment with Tween® 20 also caused the treated trimer to migrate slightly more rapidly than the untreated trimer (notice faster mobility of trimer in the + lane).
Purification of the monomeric protein yielded a homogenous preparation as evident by a single band when analyzed by reducing SDS-PAGE (Figure 1, left panel, left lane) and Superdex 200 SEC. BN-PAGE analysis of the purified monomer, either in the presence or absence of Tween® 20 revealed a single migrating monomeric gpl20 species, devoid of any higher order oligomers, consistent with its purity on SDS-PAGE (Figure 1, right panel, gpI20-/+ lanes/
Since Tween® 20 provided a simple and mild means to obtain homogenous trimers, further characterization of the non-ionic detergent effect was performed. A purified trimer preparation containing ~30% aggregates (e.g., monomer, dimmer and trimer) was treated with Tween® 20 at final concentrations of 0.0001% to 0.1% (v/v) (Figure 2A). The SOSJP R6 aggregates were converted to trimers at concentrations of 0.1% to 0.01% (Figure 2A, lanes 3-5). No conversion was observed at Tween® 20 concentrations of 0.001 and 0.0001% (Figure 2A, lanes 6 and 7). Close examination of the 0.01% reaction (lane 5) revealed that traces of aggregate were present, thus indicating that 0.01% Tween® 20 is probably the threshold concentration. To study the kinetics of the conversion, trimer preparations containing ~30% aggregate were incubated with Tween® 20 for 0, 5 and 10 minutes prior to analysis by BN-PAGE. As shown in Figure 2B,
both the 5 minute and 10 minute incubations completely eliminated the aggregate, indicating that the kinetics of the reaction was rapid and within about a 5 minute time span.
The effect of temperature on aggregate rearrangement was also examined. Aggregate/trimer preparations were incubated with Tween® 20 either at 00C (on ice), room temperature (22- 23°C), or 37°C. As shown in Figure 2C, conversion of aggregate to trimer occurred at all 3 temperatures, indicating that the Tween® 20 effect on aggregate was independent of temperature over this range. Similar results were obtained when Tween® 80 was used instead of Tween® 20.
Similar Tween® 20 treatment of the gpl20 monomer showed that there was no difference observed in its migratory pattern either in the presence or absence of Tween® 20, indicating that Tween® 20 did not affect the gpl20 monomer (Figure 1, right panel, gpl20, -/+ lanes). In some cases, a mild increase in the staining intensity of the gpl20 monomer occurred.
To test if the detergent had a collapsive effect on another large multi-subunit protein, α-2- macroglobulin (0.2M), which is an acidic 726 kDa tetrameric glycoprotein comprised of four identical 185 kDa subunits, was incubated with Tween® 20. No change was observed in the migratory pattern of Ct2M in the presence of Tween® 20, although there was a slight increase in the staining intensity of the protein.
To examine whether Tween® 20 could convert preparations containing predominantly aggregate as the major oligomeric species to resulting trimers, a KNHl 144 SOSIP R6 preparation containing > 70% HMW aggregate was incubated with Tween® 20 and analyzed by BN-PAGE. As shown in Figure 2D, Tween® 20 was effective in converting the aggregate rich fraction to trimer (Figure 2D, left panel). Fractions of less purity containing HMW aggregate, dimers and monomers (Figure 2D, right panel, - lane, each species denoted by arrows), when treated with Tween® 20 also resulted in collapse of HMW aggregate to resulting trimer (Figure 2D, right panel, + lane). However, no effect on dimer or monomer migration was observed (Figure 2D, right panel, + lane, arrows), indicating that the Tween® 20 action was specific to KNHl 144 SOSIP R6 HMW aggregate and trimer. Consistent with previous observations, some increase in monomer staining was observed. Thus, these results indicate that JTvveen® 20 efficiently converts the KNHl 144 SOSIP HMW aggregate into trimeric form. According to this invention, Tween® 20 efficiently converted into trimers HMW preparations having greater than 10%, (e.g., greater than 10-40%), aggregate. Greater than 90-99%, or 100%, trimers were able to be recovered from non-ionic detergent-, e.g., Tween® 20, treated HMW aggregates.
SEC Analysis of KNHl 144 gpl20 monomer and SOSIP R6 gpl40 trimer:
Size exclusion chromatography (SEC) analysis was performed as a second means to characterize the molecular sizes of KNHl 144 gpl20 monomer and SOSIP R6 gpl40 trimer proteins. A Superdex 200 size exclusion column was calibrated with thyroglobulin (669 kDa), ferritin (440 kDa), BSA (67 kDa) and RNAse A (13.7 kDa) as molecular weight standards. In addition, monomeric JR-FL gpl20 was also analyzed as a control. KNHl 144 gpl20 and JR-FL gpl20 were each found to migrate at an apparent molecular weight of 210 kDa. These values are consistent with those found for JR-FL gp!20 (10).
To further study the oligomeric nature of the KNHl 144 SOSIP R6 gpl40 trimer, final purified preparations were treated with Tween® 20 prior to analysis on Superdex 200 SEC to yield homogenous and unambiguous trimer samples devoid of HMW aggregate. Initial studies showed re-formation of HMW aggregate when treated trimer samples were resolved in non-detergent TN-500 buffer on the SEC column. The resulting mixed trimer-aggregate fractions, presumably re-formed upon separation of the Tween® 20 from the gpl40 oligomers in non-detergent buffer, was considered unsuitable for SEC analysis due to its heterogeneous nature.
In order to maintain homogenous (rimers, treated trimer was resolved in the presence of TN-500 containing 0.05% Tween® 20 (TNT-500). As shown in Figure 3, {bottom panel BN-PAGE), the trimer {thick arrow) migrated from fractions BlO through C2, represented in the major peak, with its peak signal at fraction B12 {vertical arrow). The retention time at this fraction corresponds to an apparent calculated molecular weight of ~518 kDa. The reported apparent molecular weight (MW) of JR-FL SOSIP gpl40 trimer calculated via Superdex 200 SEC analysis is -520 kDa (9); and thus, the calculated apparent MW value for KNHl 144 SOSIP R6 gpl40 trimer is consistent with MW values of other SOSIP envelope trimers.
Effect of Tween® 20 Treatment on KNHl 144 SOSIP R6 Antigenicity:
Studies of the antigenic properties of unpurified KNHl 144 SOSIP R6 gpl40 (19) showed that it was immunoprecipitated by the neutralizing molecules 2G12, bl 2, CD4-IgG2, as well as the non-neutralizing mAb b6. The experiments described herein further assessed the effect of the Tween® 20 aggregate collapse on the antigenic properties of KNHl 144 SOSIP HMW aggregates to determine if conversion of HMW aggregate into trimer favorably enhanced antigenicity.
SEC fractions containing > 80% KNHl 144 SOSIP R6 HMW aggregate content (as shown in Figure 2D, - lane) were either untreated or Tween® 20 treated (typical reaction is represented in Figure 2D). The antigenicity of the proteins in the presence and absence of Tween® 20 was examined using a lectin based ELISA. These results are shown in Figure 3A. AU the anti-env antibodies and CD4-IgG2, displayed increased binding to the Tween® 20 treated aggregate. The above experiments were performed on Tween® 20 converted trimer, using preps containing >80% HMW aggregate.
To demonstrate that Tween® 20 treatment did not unfavorably disrupt the above antibody epitopes on trimers, similar lectin ELISAs were performed using 2Gl 2, b6, bl2 and CD4-ϊgG2 on SOSIP R6 gpl40 trimers that contained low amounts of HMW aggregate (- 10-15% content) that were either untreated or treated with Tween® 20. As shown in Figure 3B, no significant differences were observed in the antigenicity of trimer in presence or absence of Tween® 20. Unfortunately, since the HMW aggregate species is present in very limiting quantities, the Tween® 20 effect was assessed using only the above mentioned mAbs. These results show that Tween® 20 treatment and consequential conversion of HMW aggregate to resulting trimer enhances epitope exposure for Env binding antibodies. Thus Tween® 20 treatment and presence may offer favorable consequences in the context of KNHl 144 SOSIP R6 gpl 40 trimer stability and antibody epitope exposure.
Effect of Tween® 20 Treatment on the Ionic Properties of KNHl 144 SOSIP R6 gpl40 trimer: DEAE anion exchange chromatography was used to examine the effect of Tween® 20 on the ionic properties of SOSIP R6 gpl40 and control proteins. Untreated or Tween® 20 treated KNHl 144 SOSIP R6 gpl40 trimer spiked with a2M contaminating protein (which is unaffected by Tween® 20 and binds to anion exchange resins) were applied over DEAE anion exchange column (Figure 4, Load). The column was washed and eluted and fractions were analyzed via BN-PAGE and Coomassie staining and is shown in Figure 4. As expected, untreated SOSIP R6 gpl40 trimer and the aaM contaminant bound to the DEAE column and were recovered in the elution fraction (Figure 4, Untreated control, top panel, denoted by asterisks). However, upon treatment with Tween® 20, the KNH 1144 SOSIP R6 gpl40 trimer was found in the flow- through (FT) fractions of the column (Figure 4, Tween® 20 treated, bottom panel, FT, denoted by asterisks), indicating that it did not bind to the DEAE, unlike the untreated trimer. Residual trimer is further recovered in the wash fraction (Figure 4, Wash). In contrast, the a2M contaminant, which was used as the internal control, bound to the DEAE column and was
/
recovered in the elution, indicating that it was unaffected by the presence of Tween® 20 (Figure I3 Tween® 20 treated, bottom panel, Elution).
In other similar experiments, in which BSA, another acidic protein was substituted as the contaminant, similar results were obtained. This indicates that Tween® 20 treatment may exert its action on KNH 1144 SOSIP R6 HMW aggregate and trimer through a combination of hydrophobic interactions that possibly involve perturbations in inter- and/or intra-subunit charge- charge interactions, as examined by DEAE anion exchange chromatography.
Electron Microscopy and Digital Imaging of KNHl 144 SOSIP R6 gpl40 trimers:
Electron microscopy was performed on purified SOSIP R6 preparations employing negative stain EM analysis. The results, shown in Figure 6, reveal that the majority of the observed structures displayed a regular compact morphology with approximate three-fold symmetry. This tri-lobed configuration is most apparent in preparations with deeper stain (Figure 6; panel of trimers) that are less subject to the flattening that can occur in thinner staining preparations.
Initially, for the EM studies, it was found that the uranyl formate negative straining technique was not compatible with detergent-containing buffers. However, some trimeric structures of the anticipated dimensions were observed in the poorly staining preparations. Thereafter, the KNHl 144 SOSIP preparation was subjected to a detergent removal protocol, which yielded improved staining. Following detergent removal, the majority of the observed structures displayed a regular compact morphology with approximate three-fold symmetry (e.g., Fig. 6). This configuration is most apparent in preparations with deeper stain (Fig. 6B) that are less subject to the flattening that can occur in thinner staining preparations (Fig 6A).
In order to calculate diameters of the trimers, 70 spikes in the shallow stain samples were scored and a diameter of 13.5 ± 1.73 nm was calculated. Seventy eight (78) trimers from the deep stain were scored and resulted in a diameter of about 1 1.6 nm ± 1.75 nm. The shallow stain preparation likely gives a slight overestimation of the size and the deep stain preparation gives a slightly underestimated size. Therefore, the true size is likely to be about 12.6 ± 1.74 nm and in line with authentic Env spikes measured in situ on both negatively stained, as well as unstained, cryo-EM preparations of SIV (36, 37). Thus the biophysical EM analysis of KNHl 144 SOSIP R6 gpl40 is in good agreement with the above biochemical data and confirms the oligomeric status of the purified KNHl 144 env complex as being trimeric.
DISCUSSION
In the context of identifying and pursuing a variety of HIV-I £nv-based protein vaccines, described herein is the purification and characterizion of a novel subtype A KNHl 144 trimeric envelope spike protein and its properties. Several novel insights were gained as a result of these studies, which revealed the biochemical effects of Tween® 20 on the oligomeric conformations of the KNHl 144 SOSIP R6 proteins. Until the present invention, only one subtype B envelope, HIV-I JR-FL has been manipulated to a purified form to mimic as closely as possible the native trimeric structure of the HIV-I viral surface envelope complex via the SOSIP technology (8-11, 15-17). The present invention provides another clade, clade A KNHl 144, for which the SOSIP technology results in purified trimeric envelopes that are stable, soluble, and fully cleaved.
The purification process implemented according to the present invention for the KNHl 144 SOSIP trimers provides a marked improvement over that utilized for JR-FL SOSIP gpl40 trimers. For the KNHl 144 SOSIP1, the GNA lectin column provided a significant enrichment of gpl40 proteins, but elution off the column significantly destabilized the gpl40 trimers, resulting in a compromise of trimer fidelity on the column. As a result, significant dissociation of the trimer to resulting dimer and monomer was noticed. This destabilization could be brought about from Galanthus Nivalis lectin binding to αl-3 and αl-6 mannose linkages on the gpl40 high mannose chains, which are internal linkages and not terminal linkages (20). During elution, the affinity of the lectin for the mannan is likely much higher than the intersubunit protein-protein affinities of the 3 gp!20-gp41Ecτo monomers contributing to trimer formation, resulting in destabilization and dissociation into component dimers and monomers. To alleviate some measure of the destabilization that could be caused due to resulting sheer stresses during elution, a one hour incubation in MMP eluting buffer was included. So while a highly enriching step, the lectin affinity column also decreased the final yield of trimer significantly, due to its dissociation during the elution phase.
The next step in the purification, Superdex 200 SEC, while somewhat efficient in resolving away monomer, was not very effective in resolution of dimer from trimer. The incorporation of a DEAE weak anion exchange chromatography step was very efficient in resolving dimer (and residual monomer) away from trimer, resulting in trimeric KNHl 144 SOSIP R6 gp!40 of high purity. Notably, binding (and retention) of the trimer occurred under a relatively polar environment (yis-ά-vis ion exchange) at 75 mM NaCl, while dimer and monomer flowed through the DEAE column under these conditions.
It is relevant to extrapolate from its behavior on anion exchange chromatography that the nature of the KNHl 144 SOSIP R6 g!40 trimer is that of an acidic protein, which would be contrary to its predicted basic isoelectric point (pi) of 8.73 calculated for the protein backbone. However, the likely presence of the predicted acidic sialylated complex oligosaccharide chains on the gpl40 (21, 22) would contribute to a decrease in the overall charge of the glycoprotein and thus confer on it properties of an acidic protein. Indeed, analysis of purified KNHl 144 SOSIP R6 gpl40 trimers on isoelectric focusing gels reveal it to migrate at a pi range of 5.9 to 6.1, consistent with the above observations.
The purified trimer was shown to contain variable amounts of HMW aggregate (Figure 1, right panel, BN-PAGE), which could not be attributed to being formed at any one particular step of the purification, although one possibility might be at the lectin elution step. As mentioned before, one of the key improvements made in this purification protocol is absence of SDS-insoluble aggregates in the final prep, which are formed by abberantly formed disulfide bonds and are visualized by their slow migration on a non-reduced SDS-PAGE. As detected by Coomassie staining and confirmed by anti-envelope Western blot, little to no SDS-insoluble aggregates were observed (Figure 1, left and middle panels, Non-Red SDS-PAGE and Anti-Env blot). This is in contrast to what was observed with JR-FL SOSIP gpl40 (R6 and non-R6 versions), where SDS- insoluble aggregates comprised a significant percentage of the final preparations (9, 10, 11).
Based on observations regarding non-ionic detergent treatments of KNHl 144 SOSIP R6 gpl40 trimers (19), Tween® 20 was used to address the co-purifying HMW aggregate present in the final trimer preparations. Tween® 20 was chosen because initial observations had shown that Tween® 20 treatment was mild and did not result in any detectable monomer formation, unlike treatment with the other non-ionic detergents NP-40 and Triton X-IOO, where dinners and monomers were observed upon treatment (19). Tween® 20 treatment of the final purified KNHl 144 SOSIP R6 trimer preparation was highly reproducible and resulted in the "conversion" of the HMW aggregate species, as shown in Figure 1 (right panel, BN-PAGE). Since this resulted in a single, homogenous, oligomeric species of KNHl 144 SOSIP R6 gpl40 trimers, we routinely incorporated it as the final step in our preparations. Further analysis using reduced SDS-PAGE gels showed that the purified trimer was fully cleaved, with practically undetectable uncleaved protein (as visualized by both Coomassie staining and Western blot analysis) (Figure 1, left panel. Red SDS-PAGE). The initial purifications were performed using a non-R6 version of KNHl 144 SOSIP gpl40, which resulted in -40-50% of uncleaved protein in the final preparation, prompting the development of the R6 version. This also represents another
improvement over JR-FL SOSIP R6 gpl40 trimers, where cleavage of gp!20-gp4lEcτo was not as efficient (9, 11).
In order to expand the initial Tween® 20 observations to the stability of HMW aggregates, a variety of experiments were performed to characterize the effect of Tween® 20 and to better understand its mechanism of action. As shown in Figure 6, the effect of Tween® 20 is dose dependent, time dependent and temperature independent within the parameters that were examined. Its effect is remarkably specific to KNHl 144 SOSIP R6 HMW aggregate and trimers and has no effect on gpl20 monomers, or KNHl 144 SOSIP R6 dimers. In addition, other similar large, macromolecular, acidic proteins such as a2M are not affected by the detergent. Initially, the hypothesis was that the Tween® 20 specifically interacted with points of gpl20- gp4lEcτo intersubunit contact within the HMW aggregate, presumably in a hydrophobic manner. In this context, the HMW aggregate would have to be comprised of some multiple of trimer (most likely a dimer of trimers), since detergent treatment specifically results in a "rearrangement" to a trimeric configuration. The specificity of this reaction can further be defined by the observation that dimeric KNHl 144 SOSIP R6 gpl40 proteins are unaffected and do not undergo the collapse (Figure 6D). In addition, Tween® 20 treatment would also seem to cause the trimer to assume a more compact configuration, as evident by its slightly more rapid mobility on BN-PAGE (Figure 1).
While the anti-flocculatory effects of non-ionic detergents on aggregates of macromolecular proteins such as antibodies (immunoglobulins, for example) are well known and documented, the mechanisms of their actions have been realized to be largely by pre-emption of unfavorable hydrophobic interactions by detergent intercalation. Tween® 20, however, would seem to exert its action in a somewhat paradoxical mechanism, since treatment of the KNHl 144 SOSIP R6 gpl40 trimer with the detergent renders it unable to interact with anion exchange resins such as DEAE (Figure 1, bottom panel, Tween® 20 treated), indicating that the overall charge of the trimer was being affected by the detergent.
Since the nature of non-ionic detergents is exactly that, i.e., non-ionic, it is difficult to realize how an uncharged molecule such as Tween® 20 would affect the charge status of a large, macromolecular oligomer such as the KNHl 144 SOSIP R6 trimer. Furthermore, this effect is highly specific to the trimer, as other such large, highly charged (acidic) oligomeric proteins such as a∑M and even smaller ones such as BSA are unaffected by the detergent. One hypothesis that has emerged from this invention is that perhaps the Tween® 20 was "coating" the trimer in a
manner that may cause perturbations in its conformation, resulting in its "compactness". These perturbations would be of a subtle nature which involve the various points of contact between the individual component gpl40 monomers, causing disruption and destabilization of interactions that favor the HMW aggregate conformation. A consequence of these perturbations would be "shielding" of ionic charges that would normally be exposed (and contribute to binding to ion exchange resins). It is reasonable to speculate that perhaps the charges that are "shielded" are those on the sialic acid residues of the complex carbohydrate chains, since these would be most likely to be highly exposed at the surface (21, 22). Tween® 20 and Tween® 80 are polyoxyethylene sorbitan esters of fatty acids and thus may likely interact with the sialic acids, causing a charge "neutralization" effect. The involvement of the sialic acid residues can be investigated by mild sialydase treatment (21, 22) and removal of these residues, followed by Tween® 20 treatment, followed by monitoring of binding on ion exchange resins.
To further biochemically characterize the purified KNH 1144 monomeric and trimeric envelope proteins, size exclusion chromatography analyses were performed in order to ascertain their apparent molecular masses. These were performed on Tween® 20 treated trimers that were devoid of any HMW aggregates and thus consisted of only one homogeneously oligomeric species, i.e., the trimer, and therefore would yield unambiguous results. The retention times of the KNHl 144 SOSIP R6 gpl40 trimer resulted in a calculated apparent molecular weight of -518 kDa. This is consistent with the reported calculated apparent molecular weight of 520 kDa for the other SOSIP gpl40 trimer, JR-FL SOSIP gpl40 (9). The predicted molecular weight for a trimer such as KNHl 144 (and JR-FL) would be -420 kDa (3 x 140 kDa monomers). Thus, similar to JR-FL SOSIP gpl40, the KNHl 144 SOSIP R6 gpl40 trimer also exhibits an abberant migration on SEC, presumably due to interactions of its ΛMinked glycans with the dextran- (agarose polymer) based matrix of Superdex 200, resulting in a higher than expected apparent molecular mass. In addition, envelope proteins have been shown to be non-globular in shape (10, 23, 24); therefore, gel filtration may not be optimal for determination of their precise molecular masses. This also extends to the KNHl 144 gpl20 monomer as well. Values of —210 kDa were obtained for KNHl 144 gpl20 and the control JR-FL gp!20. The reported value for JR-FL gpl20 is 200 kDa (10); accordingly, the obtained values are well within the expected range (given that molecular weight determination via SEC is not extremely accurate, unlike other methodologies such as mass spectrometry). Thus, gpl20, whose predicted molecular weight ranges from ~95 to —120 kDa, results in an abberant migratory pattern on SEC, presumably due to its glycan interactions with the sizing column matrix. It should be noted that unlike the KNHl 144 SOSIP R6 gpl 40 trimer, migration of KNHl 144 gpl20 (and JR-FL gp!20) were not
W
35 affected by the presence or absence of Tween® 20, consistent with the initial BN-PAGE observations (Figure I, right panel, gpl20).
While it would seem that the presence of Tween® 20 for KNHl 144 SOSIP R6 gpl40 proteins would be advantageous, possible Tween® 20 effects on the antigenicity of the HMW aggregate and trimer were examined. Effects on antigenicity was examined by performing lectin ELISAs with the NAbs 2G12, bl2, HIVIg, the CD4-IgG2 antibody conjugate PRO 542, as well as the non-neutralizing mAb b6, to gain information on neutralizing/non-neutralizing epitope exposure and accessibility- It was reasoned that trimer preparations containing 10-30% HMW aggregate may not undergo significant enough changes that would be detectable in a non-quantitative assay such as IPs, i.e., subtle changes (20-30% changes) may go undetected in such an assay due to sensititivity. However, samples representing extremes may undergo significantly high changes that should be detectable in an assay format such as ELISA. Therefore, SEC fractions that contained > 80% HMW aggregate were used, which would reflect one extreme prior to Tween® 20 treatment and the resulting trimer, which would reflect the other extreme post treatment. A representative reaction of this is illustrated in Figure 2D.
As shown in Figure 4A, significant epitope exposures were observed upon Tween® 20 rearrangement of the HMW aggregate to trimer, and these changes were noticed for all of the anti-env agents. These changes indeed were not as apparent in trimer preparations that were predominantly trimer, with low aggregate content (10-15%) (Figure 4B). Thus the treated, purified trimer displays antigenic properties similar to that which was previously observed with crude, unpurified trimer supernatants, i.e., binding to 2G12, b6, b!2 and PRO 542 (19). In the context of HIVIg, which is a low neutralizing polyclonal human antisera directed against gpl20 hypervariable loop (40), it can be inferred that this epitope is accessible on the surface of the HMW aggregate, based on its ability to bind the antibody in absence of Tween® 20. Consistent with the other anti-Env agents examined here, HIVIg epitope exposure also significantly increased on the rearranged trimer, upon treatment with Tween® 20. The likely explanation to these increases in epitope exposure is that "disruption/rearrangement" of the aggregate and its subsequent conversion to trimer unshields the above mentioned surfaces and thus, upon conversion, these surfaces are now exposed on their individual trimers and are accessible to the antibodies. From the context of a single HMW aggregate which is likely to be a multimer of trimers, only a small portion of these epitopes are accessible, most probably due to steric hindrance from adjacently "clumped" SOSIP R6 trimers/oligomers. When the single HMW aggregate is then Tween® 20 converted to resulting trimers, antibody epitopes are now exposed
on every one of the resulting individual component trimers, resulting in an increase in antibody accessibility and binding. Thus Tween® 20 treatment and its conversion of the aggregate to trimer do not seem to have detrimental effects on antigenicity and may be favorable to the structural properties of the KNHl 144 SOSIP R6 gpl40 proteins.
Analysis of KNHl 144 SOSIP R6 gpl40 proteins by negative stain EM further confirmed the biochemical observations that these gpl40 proteins were indeed trimeric in nature (Figure 6). A distinguishing feature of the KNHl 144 SOSIP R6 construct, in comparison to other similar constructs of trimerized gpl20 and gpl40, is its compact nature. Most other constructs show either predominantly loosely associated subunits or a mix of loosely and tightly associated subunits (5, 18, 38). The observation that the KNHl 144 SOSIP R6 trimer is compact is associated with anti-Env antibody epitope availability. EM on Tween®-treated trimer which has favorable anti-Env epitope exposure was performed. It is somewhat incongruous from a purely steric standpoint that a "compact" trimer would also have improved epitope exposure, a consequence expected from a "loose" or "elongated" structure. Immunoelectron microscopy analyses with the above mentioned antibodies will further address the exposure of epitopes on trimeric forms.
The present invention expands the panel of trimeric HTV-I envelope proteins that may be used as protein-based HIV-I vaccine candidates or serve as a template for future design of Env based protein vaccine candidates, using the SOSIP technology. Immunological studies in rabbits with JR-FL SOSIP R6 gpl40 trimers, while effective in eliciting NAbs, were limited in their breadth of neutralization of primary HIV-I isolates (11). Factors associated with the biochemical nature of the JR-FL SOSIP gpl40 and other oligomeric Env proteins that are thought to limit their observed immunological response in animals, such as inefficient furin cleavage of the gpl20- gp4lEcτo cleavage site giving rise to heterogenous trimers (containing both cleaved and uncleaved trimers), presence of SDS-insoluble aggregates and presence of undesirable gpl40 oligomers such as dimers and monomers (5, 6, 9, 10, 1 1, 27-30) have been issues needing resolution.
The description of the KNHl 144 SOSIP R6 gpl40 trimers of the present invention addresses most of these issues. Furthermore, the description of the Tween® 20 affects on coverting HMW aggregates to trimeric forms further expands on current knowledge of the aggregate species in HIV-I biology. Of significance, it was shown for the first time, that oligomeric Env protein complexes designed using the SOSIP technology platform are indeed trimeric from EM images
and that the trimers are of a similar diameter as native spikes on the HIV-I virion (36, 37). Expansion of the panel of potential HIV-I SOSIP protein vaccine candidates by development of a clade A envelope according to this invention now allows for immunological evaluation of the KNHl 144 SOSIP R6 gpl40 trimer in small animals, for example. Such evaluations will assist in S determining the efficacy of KNHl 144 SOSIP R6 gpl40 trimers as immunogens capable of eliciting broadly neutralizing immune responses directed against HIV-I.
REFERENCES
I . UNAIDS: AIDS Epidemic Update: December 2005, ISBN 92 9 173439 X. 0 2. Kijak, G. H., and McCutchan, F. E. (2005) Curr Infect Dis Rep. 7, 480-488.
3. Jeffs, S. A., Goriup, S., Kebble, B., Crane, D., Bolgiano, B., Sattentau, Q., Jones, S., and Holmes, H. (2004) Vaccine. 22, 1032-1046.
4. Srivastava, I. K., Stamatatos, L., Legg, H., Kan, E., Fong, A., Coates, S. R., Leung, L., Wininger, M., Donnelly, J. J., Ulmer, J. B., and Barnett, S. W. (2002) J Virol. 76, 5 2835-2847.
5. Srivastava, I. K., Stamatatos, L., Kan, E., Vajdy, M., Lian, Y., Hilt, S., Martin, L., Vita, C, Zhu, P., Roux, K. H., Vojtech, L., Montefiori, D. C, Donnelly, J., Ulmer, J. B., and Barnett, S. W. (2003) J Virol. 11, 11244-11259.
6. Yang, X., Florin, L.s Farzan, M., Kolchinsky, P., Kwong, P. D., Sodroski, J., and 0 Wyatt, R. (2000) J Virol. 74, 4746-4754.
7. Grundner, C, Li, Y., Louder, M., Mascola, J., Yang, X.} Sodroski, J., and Wyatt R. (2005) Virology 331, 33-46.
8. Binley, J. M., Sanders, R. W., Clas, B., Schueike, N., Master, A., Guo, Y., Kajumo, F., Anselma, D. J., Maddon, P. J., Olson, W. C, and Moore, J. P. (2000) J Virol. 74, 627- 5 643.
9. Sanders, R. W., Vesanen, M., Schueike, N., Master, A., Schiffner, L., Kalyanaraman, R., Berkhout, B., Maddon, P. J., Olson, W. C, Lu, M., and Moore, J. P. (2002; J Virol. 76, 8875-8889.
10. Schulke, N., Vesanen, M. S., Sanders, R. W., Zhu, P., Lu, M., Anselma, D. J., Villa, A. 0 R., Parren, P. W., Binley, J. M., Roux, K. H., Maddon, P. J., Moore, J. P., and Olson,
W. C. (2002) J Virol. 76, 7760-7776.
I 1. Beddows, S., Schulke, N., Kirschner, M,, Barnes, K., Franti, M., Michael, E., Ketas, T., Sanders, R. W., Maddon, P. J., Olson, W. C, and Moore, J. P. (2005) J Virol. 79, 8812-8827. 5 12. Emini, E. A. and Koff, W. C. (2004) Science 304, 1913-1914.
13. Poignard, P., Saphire, E. O., Parren, P. W., and Burton, D. R. (2001) Annu Rev Immunol. 19, 253-274.
14. Wyatt, R., and Sodroski, J. (1998) Science 280, 1884-1888.
15. Sanders, R. W., Schiffner, L., Master, A., Kajumo, F., Guo, Y., Dragic, T., Moore, J. P., and Binley, J. M. (2000) J Virol. 74, 5091-5100.
16. Binley, J. M., Sanders, R. W., Master, A., Cayanan, C. S., Wiley, C. L., Schiffner, L., Travis, B., Kuhmann, S., Burton, D. R., Hu, S. L., Olson, W. C1 and Moore, J. P. (2002) J Virol. 76, 2606-2616.
17. Binley, J. M., Cayanan, C. S., Wiley, C, Schulke, N., Olson, W. C, and Burton, D. R. (2003) J Virol. 77, 5678-5684.
18. Pancera, M., Lebowitz, J., Schon, A., Zhu, P., Freire, E., Kwong, P. D., Roux, K. H., Sodroski, J., and Wyatt, R. (2005) J Virol. 79, 9954-9969.
19. Beddows, S., Kirschner, M., Campbell-Gardener, L., Franti, M., Dey, A, K., Iyer, S, N., Paluch, M., Master, A., Overbaugh, J., VanCott, T., Olson, W. C, and Moore, J. P. (2006) AIDS Res Hum Retroviruses (in press).
20. Botos, I., and Wlodawer, A. (2005) Prog Biophys MoI Biol. 88, 233-282.
21. Scanlan, C. N., Pantophlet, R., Wormald, M. R., Ollmann, Saphire, E., Stanfϊeld, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M., and Burton, D. R. (2002) J Virol. l6, Ti06-Ti2\. 22. Sanders, R. W., Venturi, M., Schiffher, L., Kalyanaraman, R., Katinger, H., Lloyd, K.
O., Kwong, P. D., and Moore, J. P. (2002) J Virol. 76, 7293-7305.
23. Center, R. J., Earl, P. L., Lebowitz, J., Schuck, P., and Moss, B. (2000) J Virol. 74, 4448-4455.
24. Center, R. J., Schuck, P., Leapman, R. D., Arthur, L. O., Earl, P. L., Moss, B., and Lebowitz, J. (2001) Proc Natl Acad Sci USA. 98, 14877-14882.
25. Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., AUaway, G. P., Katinger.H., Barbas, C. F. 3rd, Burton, D. R., Ho, D. D., and Moore, J. P. (1995) J Virol. 69, 6609-6617.
26. Trkola, A., Purtscher, M., Muster, T., Ballaun, C, Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., and Katinger, H. (1996) J Virol. 70, 1100-
1 108.
27. Center, R. J., Lebowitz, J., Leapman, R. D., and Moss, B. (2004) J Virol. 78, 2265- 2276.
28. Chakrabarti, B. K., Kong, W. P., Wu, B. Y., Yang, Z. Y., Friborg, J., Ling, X., King, S. R., Montefiori, D. C, and Nabel, G. J. (2002) J Virol. 76, 5357-5368.
29. Zhang, C. W., Chishti, Y., Hussey, R. E., and Reinherz, E. L. (2001) J Biol Chem. 276, 39577-39585.
30. Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R., and Sodroski, J. (2002) J Virol. 76, 4634-4642. 31. Lian, Y., Srivastava, I., Gomez-Roman, V. R., Zur Megede, J., Sun, Y., Kan, E., Hilt,
S., Engelbrecht, S., Himathongkham, S., Luciw, P. A., Otten, G., Ulmer, J. B., Donnelly, J. J., Rabussay, D., Montefiori, D., van Rensburg, E. J., and Barnett, S. W. (2005) J Virol. 79, 13338-13349.
32. Roben, P., Moore, J. P., Thali, M., Sodroski, J., Barbas, C. F. 3rd., and Burton, D. R. (1994) J Virol. 68, 4821 -4828.
33. Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., Lamacchia, M., Garratty, G., Stiehm, E. R., Bryson, Y. J., Cao, Y., Moore, J. P., Ho, D. D., and Barbas, C. F. 3rd. (1994) Science 266, 1024-1027. 34. Roux, K. H. (1989) Methods Enzymol. 178, 130-144.
35. Roux, K. H. (1996) Methods 10, 247-256.
36. Zhu, P., Chertova, E., Bess, J., Jr., Lifson, J. D., Arthur, L. O., Liu, J., Taylor, K. A., and Roux, K. H. (2003) Proc Natl Acad Sci USA. 100, 15812-15817.
37. Qiao, Z. S., Kim, M., Reinhold, B., Montefiori, D., Wang, J. H., and Reinherz, E. L. (2005) J Biol Chem. 280, 23138-23146.
38. Olson, W. C, and Maddon, P. J. (2003) Curr Drug Targets Infect Disord. 3, 255-262.
EXPERIMENTAL DETAILS II
MATERIALS AND METHODS
Subtype B 5768.4 SOSIP R6 gpl40 expression and purification: The subtype B 5768.4 envelope sequence has been described (8). The sequence was modified to make the soluble SOSIP R6 gpl40 version, as described above for the KNHl 144 isolate in the section "Experimental Details I" and for the JR-FL SOSIP R6 gpl40 trimers (3, 4). DNA synthesis was performed by DNA 2.0 (Menlo Park, CA). The 5768.4 SOSIP R6 gpl40 trimer was expressed in HEK293 and small scale (2 L) purification was performed as described above for KNH 1 144 SOSIP R6 gp 140.
Detergent Aggregate "Collapse"/"Conversion" Experiments:
Tween® 20 Dose effect: 1 ug of purified 5768.4 SOSIP R6 trimer was incubated with varying concentrations of Tween® 20 ranging from 0.1 to 0.0001% (v/v) and incubated for 1 hour at room temperature. Following incubation, samples were analyzed by BN-PAGE as described above.
Detergent effect on 5768.4 SOSIP R6 gpJ40 trimer preparations: 0.24 ug of purified 5768.4 SOSIP R6 trimer was incubated with Triton X-IOO, NP-40, or SDS to a final detergent concentration of 0.1% (v/v) or with Tween® 20 at concentrations of 0.05 and 0.1% for 1 hour at room temperature. Following incubation, 4x BN-PAGE MOPS sample buffer was added and the samples were immediately analyzed on BN-PAGE at 150 V for 2 hours at room temperature, followed by Coomassie G-250 staining.
Size exclusion chromatography (SEO analysis:
All runs were performed at 4°C on the AKTA FPLC system (GE Healthcare). Each run was performed at least twice.
Molecular weight standards SEC: Superdex 200 10/300 GL column was equilibrated in 20 mM Tris pH 8, 0.5 M NaCl (TN-500) and calibrated with the following molecular weight standard proteins: thyroglobulin 669,000 Da; ferritin 440,000 Da; BSA 67,000 Da; RNAse A 13,700 Da. A standard curve was generated by plotting the observed retention volumes of the standard proteins against the log values of their predicted molecular weights.
Blue Native PAGE CBN-PAGE). SDS-PAGE and Western blot analysis:
AU SDS-PAGE analysis (reduced and non-reduced) were performed using 4-12% Bis-Tris NuPage gels (Invitrogen). BN-PAGE analysis was performed as described before (1-3). Silver staining analysis was performed with the SilverQuest kit (Invitrogen).
RESULTS AND DISCUSSION
Detergent "collapse" effect on subtype B 5768.4 HMW aggregate:
Detergent treatments were performed on a trimeric gpl40 of a different subtype 5768.4, which is a subtype B envelope (8). The 5768.4 Env protein was modified to the SOSIP R6 version, expressed and purified as a gpl40 trimer. The purified final preparation contained high HMW aggregate content (~60%) and minor a2M contamination (~5%), with trimer comprising the rest. Purified preparations were incubated with the various indicated detergents (Triton X-IOO, NP40, SDS, or Tween® 20) and were treated to collapse HWM aggregate.
Tween® (Tween® 20 and Tween® 80) effectively collapsed HMW aggregate to trimers at 0.1 and 0.05% concentrations. Triton X-100 was also capable of collapsing HMW aggregate to trimer, however, some breakdown to monomeric 5768.4 was observed. As expected, SDS was effective in breaking down the entire 5768.4 gpl40 protein to resulting monomers by virtue of its denaturing effect on the trimer and HMW aggregate. NP40 treatment also led to collapse of HMW aggregate to trimer, but the resulting trimer displayed a somewhat broader staining compared with that of Tween® 20 treated trimers. Thus, the detergent effect, in particular, Tween® 20, on the HMW aggregate is not unique to KNHl 144 SOSIP gpl40 Env proteins and exhibits similar HMW aggregate collapse ability on other subtypes of HIV envelope trimers as well, such as the 5768.4 SOSIP R6 gpl40.
REFERENCES FOR EXPERIMENTAL DETAILS II
1. Schulke et. al, 2002, Journal of Virology 76: 7760-7776. 2. Binley et. al, 2002, Journal of Virology 76: 2606-2616.
3. Beddows et. al, 2005, Journal of Virology 79: 8812-8827.
4. Sanders et. al, 2002, Journal of Virology 76: 8875-8889.
5. Grunder et. al, 2005, Virology 331: 33-46.
6. Pancera et. al, 2005, Journal of Virology 79: 9954-9969.
7. Trkola et. al, 1996, Nature 384: 184-187.
8. Li et. a\, 2005, Journal of Virology 79: 10108-10125.
EXPERIMENTAL DETAILS in
Purification of SOSlP Env Trimers:
An efficient purification process was developed to purify SOSlP Env trimers and to increase the yield of trimers. This process is exemplified by using a preparation, e.g., a cell culture fluid containing KNHl 144.R6 SOSIP proteins, to purify KNHl 144.R6 SOSIP trimers.
In this process, concentrated cell culture fluid (CCF) preparation containing KNHl 144 SOSIP.R6 gpl40 trimers, dimers and monomers was subjected to ammonium sulfate precipitation at 4°C to remove contaminant proteins, e.g. macrogJobulin. The resulting supernatant was applied to a lectin (Galanthus Nivalis Lectin (GNL) Vector Laboratories Burlingame, CA) chromatography column (e.g., GEHC (GE Healthcare XK), at 4°C. A linear gradient elution was used and bound proteins were eluted to PBS, pH 7.25, 1. 0 M methyl-a-D- mannopyranoside (MMP) in ten column volumes (CV) followed by 5 CV at 100% PBS, pH 7.25 +1.0 M MMP. Fraction size was 0.5 CV and about 30 fractions were collected. Macroglobulin and monomer eluted first and were essentially removed from the trimer product. Column fractions were analyzed by gel electrophoresis (BN-PAGE) and the fractions enriched in trimer were pooled based on the gel analysis.
The trimer-containing eluted fractions from the lectin chromatography column were applied to a first DEAE sepharose column (DEAE 1) in the absence of Tween 20®. A 5-ml HiTrap DEAE FF sepharose column (GE Healthcare/Amersham Biosciences Piscataway, NJ) was used in this step. The DEAE 1 chromatography was performed at room temperature. The column equilibration buffer comprised 20 mM Tris, 0.075 M NaCl, pH 8.0, and the column equilibration flow rate was 10 ml/min. The column loading and elution flow rate was 2.5 ml/min with a fraction size of 2.5 ml. The high flow rate allowed this step to be completed in a short amount of time. The KNH1 144.R6 gpHO trimer product was eluted from DEAE 1 in several fractions through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes (10 CV). KNHl 144 SOSIP.R6 gpl40 monomers and dimers were removed in the flow through and wash step using 20 mM Tris, 75 mM NaCl (pH 7.5) at room temperature.
A second Hi-Trap DEAE FF sepharose column (DEAE 2) was equilibrated with buffer containing Tween 20® (20 mM Tris, 75 mM NaCl, 0.05% Tween, pH 8.0). The DEAE 2 chromatography was also performed .at room temperature. The DEAE 1 elution fractions containing KNHl 144 SOSTP .R6 trimers in buffer also containing Tween 20® was applied to the second DEAE column. The KNHl 144 SOSIP.R6 trimer product was obtained in the flow- though and in the wash pool, since KNHl 144 SOSIP.R6 trimer did not bind to the DEAE column in the presence of Tween 20® in the buffer. A suitable range of Tween 20Cg) for purification of the SOSIP.R6 trimers is 0.025% to 1%. 0.05% Tween 20® was used in many purification runs.
In this example, a high quality KNH 1144 SOSIP.R6 trimer product was purified as shown in Figures HA and HB. Only a single band was observed in the BN-PAGE analysis (Fig. 11A). SDS-PAGE analysis demonstrated that there was no uncleaved gpl40 in the product (Fig. 1 IB). A high purity trimer product was obtained using the above-described process compared with other purification methods, as shown in Figures 12A and 12B. The immunogenicity of the KNHl 144 SOSIP.R6 trimer product was also tested by immunoprecipitation (IP) experiments, e.g., as shown in Figure 13 using ARP 3119 probing antibody (also known as CA13) (MRC Centralized Facility for AIDS reagents, NIBSC, UK). 2G12, bl2, b6, and 15e are HTV neutralizing antibodies used in the IP experiment. PRO542 is a CD4-IgG2 heterotetrameric protein. 75 ug KNHl 144 SOSIP.R6 trimer was purified using this purification method from 1 liter (IL) of cell culture fluid (CCF). At least 50ug of trimer product was recovered from IL of CCF using the purification method described in this example. The resulting purified and enriched trimer product was free from aggregates, monomers and dimers. Monomer content was less than 5% based on BN-PAGE/silver stain gel analysis.
Claims
1. A process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof which comprises treating the preparation with a non-ionic detergent so as to thereby convert the high molecular weight aggregates into trimers, and recovering the trimers from the preparation so treated.
2. The process of claim 1, wherein the retroviral Env protein is an HTV Env protein.
3. The process of claim 2, wherein the retroviral Env protein is an HIV-I or HIV-2 Env protein.
4. The process of claim 1, further comprising formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
5. A process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the Env protein and high molecular weight aggregates thereof which comprises: (a) subjecting the preparation to lectin chromatography to obtain a trimer-enriched eluate in which aggregate content is reduced; (b) applying the eluate of step (a) to a first diethylaminoethyl (DEAE) sepharose chromatography column in the absence of non-ionic detergent to obtain elution fractions further enriched in trimers; (c) applying trimer-enriched elution fractions from the first DEAE sepharose chromatography column of step (b) to a second DEAE sepharose chromatography column in the presence of non-ionic detergent; and (d) collecting the flow through and wash fractions from the second DEAE sepharose chromatography column in the presence of non-ionic detergent, so as to thereby recover the trimers of the retroviral Env protein.
6. The process of claim 5, wherein the retroviral Env protein is an HW Env protein.
7. The process of claim 6, wherein the retroviral Env protein is an HIV-I or HIV-2 Env protein.
8. The process of claim 5, wherein, in step (a), the preparation is a concentrated cell culture fluid.
9. The process of claim 5, wherein, in step (a), the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography.
10. The process of claim 5, wherein, in step (a), column fractions enriched in trimers are eluted through a linear gradient in PBS to 1.0 M methyl-a-D-mannopyranoside (MMP) in ten column volumes.
1 1. The process of claim 5, wherein, in step (b), fractions further enriched in trimers are eluted from the DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes.
12. The process of claim 5, wherein, in step (c), the fractions further enriched in trimers are eluted from the second DEAE chromatography column through a linear gradient to 20 mM Tris, 0.3 M NaCl, pH 8.0 in ten column volumes.
13. The process of claim 5, wherein the wash fractions of step (d) comprise buffer which comprises 20 mM Tris and 75 mM NaCl, pH 7.5.
14. A process of recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof, which comprises:
(a) subjecting the preparation to lectin affinity chromatography to obtain an eluate enriched in trimers and essentially separated from monomer and dimer aggregates and macroglobulin; and
(b) subjecting the eluate of step (a) to a first diethylaminoethyl sepharose chromatography column in the absence of non-ionic detergent so as to further remove aggregates in the flow through; and
(c) subjecting the eluate of step (b) to a second diethylaminoethyl sepharose chromatography column in the presence of non-ionic detergent so as to recover the trimers of the retroviral Env protein.
15. The process of claim 14, wherein the retroviral Env protein is an HIV Env protein.
16. The process of claim 15, wherein the retroviral Env protein is an HIV-I or HIV-2 Env protein.
17. The process of claim 14, wherein, in step (a), the preparation is a concentrated cell culture fluid.
18. The process of claim 14, wherein, in step (a), the preparation is subjected to ammonium sulfate precipitation prior to the lectin chromatography.
19. The process of claim 1, claim 5, or claim 14, wherein the trimers are recovered in the presence of the non-ionic detergent so as to maintain trimer stability upon subsequent storage.
20. The process of claim 1, claim 5, or claim 14, wherein the non-ionic detergent is a polyethylene type detergent.
21. The process of claim 20, wherein the polyethylene type detergent is a poly (oxyethylene) sorbitan monolaureate.
22. The process of claim 21, wherein the poly (oxyethylene) sorbitan monolaureate is poly (oxyethylene) (20) sorbitan monolaureate.
23. The process of claim 20, wherein the polyethylene type detergent is poly (oxyethylene) sorbitan monooleate.
24. The process of claim 1, claim 5, or claim 14, wherein the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HFV-I subtype A isolate or a mutant derived therefrom.
25. The process of claim 24, wherein the HIV-I subtype A isolate is KNHl 144.
26. The process of claim 1, claim 5, or claim 14, wherein the Env protein comprises consecutive amino acids having a sequence corresponding to that of a naturally occurring Env protein of an HIV-I subtype B isolate or a mutant derived therefrom.
27. The process of claim 26, wherein the HIV-I subtype B isolate is 5768.4.
28. The process of claim 5, wherein steps (a) through (d) are carried out at room temperature.
29. The process of claim 14, wherein steps (a) through (c) are carried out at room temperature.
30. The process of any of claims 1, 5, or 14, wherein the non-ionic detergent present is at a concentration of 0.001% to 1% by weight of the preparation.
31. The process of claim 30, wherein the. concentration of the non-ionic detergent is from 0.01% to 1% by weight.
32. The process of claim 31, wherein the concentration of the non-ionic detergent is from 0.025% to 1% by weight.
33. The process of claim 31, wherein the concentration of the non-ionic detergent is from 0.01% to 0.5% by weight.
34. The process of claim 33, wherein the concentration of the non-ionic detergent is from 0.01% to 0.1% by weight.
35. The process of claim 34, wherein the concentration of the non-ionic detergent is from 0.01% to 0.05% by weight.
36. The process of claim 35, wherein the concentration of the non-ionic detergent is 0.05% by weight.
37. The process of any of claims 1, 5, or 14, wherein prior to treatment with the non-ionic detergent the preparation comprises greater than 10% high molecular weight aggregates.
38. The process of claim 37, wherein prior to treatment with the non-ionic detergent the preparation comprises 10-40% high molecular weight aggregates.
39. The process of any of claims 1, 5, or 14, wherein prior to treatment with the non-ionic detergent the preparation comprises greater than 70% high molecular weight aggregates.
40. The process of any of claims 1, 5, or 14, wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HTV-I KNHl 144 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I KNHl 144 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I KNHl 144 isolate being as set forth in SEQ ID NO:2 and SEQ ID NO:3, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 51 1 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 617 and a proline at amino acid position 571, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:1, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 511 and the cysteine at amino acid position 617.
41. The process of any of claims 1, 5, or 14, wherein the Env protein comprises (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gpl20 envelope polypeptide portion of a gpl40 envelope of an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gpl40 envelope of the HIV-I 5768.4 isolate or such quasi-species thereof, the sequence of said modified gpl20 envelope polypeptide portion and said modified gp41 ectodomain polypeptide portion of said HIV-I 5768.4 isolate being as set forth in SEQ ID NO:5 and SEQ ED NO:6, respectively, said modified gpl20 envelope polypeptide portion comprising a cysteine at amino acid position 519 and said modified gp41 ectodomain polypeptide portion comprising a cysteine at amino acid position 625 and a proline at amino acid position 579, wherein (i) the amino acid positions are numbered by reference to SEQ ID NO:4, (ii) the modified gpl20 envelope polypeptide portion further comprises a mutated furin recognition sequence, and (iii) the modified gpl20 polypeptide portion and the modified gp41 ectodomain polypeptide portion are bound to one another by a disulfide bond between the cysteine at amino acid position 519 and the cysteine at amino acid position 625.
42. The process of any of claims 1, 5, or 14, wherein the recovering further comprises purifying the trimers.
43. The process of any of claims 1, 5, or 14, wherein at least 50 μg of trimers are recovered from the preparation.
44. The process of any of claims 1, 5, or 14, further comprising formulating the recovered trimers with a pharmaceutically acceptable carrier, excipient, or diluent.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07809720A EP2040746A4 (en) | 2006-06-19 | 2007-06-19 | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
CA002655929A CA2655929A1 (en) | 2006-06-19 | 2007-06-19 | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81511406P | 2006-06-19 | 2006-06-19 | |
US60/815,114 | 2006-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007149490A1 true WO2007149490A1 (en) | 2007-12-27 |
Family
ID=38833738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014388 WO2007149490A1 (en) | 2006-06-19 | 2007-06-19 | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2040746A4 (en) |
CA (1) | CA2655929A1 (en) |
WO (1) | WO2007149490A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2765138A2 (en) * | 2012-11-05 | 2014-08-13 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
WO2015171975A1 (en) * | 2014-05-09 | 2015-11-12 | The Regents Of The University Of Michigan | Use of modified banana lectin in purification of glycoproteins |
US9675685B2 (en) | 2008-12-09 | 2017-06-13 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US10426829B2 (en) | 2015-09-03 | 2019-10-01 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
WO2021089770A3 (en) * | 2019-11-07 | 2021-07-01 | Janssen Vaccines & Prevention B.V. | Protein purification |
US11278612B2 (en) | 2018-03-19 | 2022-03-22 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737067B1 (en) * | 1998-07-31 | 2004-05-18 | Aventis Pasteur S.A. | Trimer of HIV env gene expression product |
WO2004087201A2 (en) * | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005502350A (en) * | 2001-09-06 | 2005-01-27 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | Human immunodeficiency virus envelope glycoprotein variants and uses thereof |
-
2007
- 2007-06-19 WO PCT/US2007/014388 patent/WO2007149490A1/en active Application Filing
- 2007-06-19 EP EP07809720A patent/EP2040746A4/en not_active Withdrawn
- 2007-06-19 CA CA002655929A patent/CA2655929A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737067B1 (en) * | 1998-07-31 | 2004-05-18 | Aventis Pasteur S.A. | Trimer of HIV env gene expression product |
WO2004087201A2 (en) * | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
Non-Patent Citations (5)
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11052146B2 (en) | 2008-12-09 | 2021-07-06 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US10022437B2 (en) | 2008-12-09 | 2018-07-17 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9675685B2 (en) | 2008-12-09 | 2017-06-13 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9717786B2 (en) | 2008-12-09 | 2017-08-01 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9731000B2 (en) | 2008-12-09 | 2017-08-15 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
US9738688B2 (en) | 2012-11-05 | 2017-08-22 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
EP2765138A2 (en) * | 2012-11-05 | 2014-08-13 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
EP2765138A3 (en) * | 2012-11-05 | 2014-09-10 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
WO2015171975A1 (en) * | 2014-05-09 | 2015-11-12 | The Regents Of The University Of Michigan | Use of modified banana lectin in purification of glycoproteins |
US11364294B2 (en) | 2015-09-03 | 2022-06-21 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
US11253585B2 (en) | 2015-09-03 | 2022-02-22 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
US10426829B2 (en) | 2015-09-03 | 2019-10-01 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
US11278612B2 (en) | 2018-03-19 | 2022-03-22 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
US11896662B2 (en) | 2018-03-19 | 2024-02-13 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
JP7170942B1 (en) | 2019-11-07 | 2022-11-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | protein purification |
AU2020381082B2 (en) * | 2019-11-07 | 2022-09-22 | Janssen Vaccines & Prevention B.V. | Protein purification |
JP2022547341A (en) * | 2019-11-07 | 2022-11-11 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | protein purification |
WO2021089770A3 (en) * | 2019-11-07 | 2021-07-01 | Janssen Vaccines & Prevention B.V. | Protein purification |
US11857619B2 (en) | 2019-11-07 | 2024-01-02 | Janssen Vaccines & Prevention B.V. | Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein |
Also Published As
Publication number | Publication date |
---|---|
EP2040746A4 (en) | 2009-12-16 |
EP2040746A1 (en) | 2009-04-01 |
CA2655929A1 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
De Taeye et al. | Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes | |
US20110076298A1 (en) | Soluble stabilized trimeric hiv env proteins and uses thereof | |
Bhattacharya et al. | Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles | |
Moore et al. | Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1 | |
Joyce et al. | Soluble prefusion closed DS-SOSIP. 664-Env trimers of diverse HIV-1 strains | |
EP2873423B1 (en) | Soluble hiv-1 envelope glycoprotein trimers | |
Prasad et al. | Cryo-ET of Env on intact HIV virions reveals structural variation and positioning on the Gag lattice | |
US9738688B2 (en) | HIV-1 envelope glycoprotein | |
CN103992396B (en) | A kind of potential efficiently immunogenic preparation methods of 1 CRF07 BC gp140 of Recombinant HIV | |
EP2040746A1 (en) | Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins | |
EP2073840A2 (en) | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof | |
JP2005502350A (en) | Human immunodeficiency virus envelope glycoprotein variants and uses thereof | |
Wieczorek et al. | Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research | |
Sellhorn et al. | Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins | |
Si et al. | Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity | |
Center et al. | Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras | |
Blish et al. | Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes | |
Gonelli et al. | Immunogenicity of HIV-1-based virus-like particles with increased incorporation and stability of membrane-bound Env | |
JPH05505616A (en) | Purified gp120 composition retaining native conformation | |
US10005819B2 (en) | Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag | |
CHIOU et al. | Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function | |
Iyer et al. | Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers | |
Leaman et al. | Membrane Env liposomes facilitate immunization with multivalent full-length HIV spikes | |
US20110311585A1 (en) | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity | |
US9562078B2 (en) | Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07809720 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2655929 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007809720 Country of ref document: EP |